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ABSTRACT
Dharmarajan, Subramanian Ph.D., Purdue University, August 2017. Regulation Of
Gliosis In The Mouse Retina. Major Professor: Teri Belecky-Adams.
The glial cells of the retina aid in function and maintenance of the retina. The
macroglia, Mu¨ller cells and the retinal astrocytes, become reactive following in-
jury or disease in the retina, a response that is characterized by hypertrophy, de-
differentiation, loss of functionality, proliferation, and remodeling of tissue and ex-
tracellular matrix (ECM). The microglia which are the resident macrophages, also
respond to injury/disease becoming activated, undergoing characteristic molecular
and morphological changes, which include regulation of secreted factors, changes
in inflammatory response and increased phagocytosis. Reactivity in Mu¨ller glia is
thought to be the result of secreted signals, such as epidermal growth factor, ciliary
neurotrophic factor, and fibroblast growth factor, which are released at the injury site
to interact with quiescent glial cells. Furthermore, microglia and macroglia have been
shown by some studies to interact following activation. While BMPs are known to
be upregulated following injury in the CNS, little information is available concerning
their role in reactive gliosis in the retina. We hypothesize that BMP7 indirectly trig-
gers Mu¨ller gliosis by activating microglia. Using RT-qPCR, immunofluorescence and
western blot, we assessed changes in gliosis markers in the mouse retinal glia following
treatment with BMP. Our results showed that BMP7 was able to trigger Mu¨ller cell
gliosis in the retina in vitro and in vivo. Furthermore, ablation of microglia lead to a
subdued gliosis response in the mouse retina following BMP7 exposure. Thus, BMP7
triggers activation of retinal microglia in addition to the Mu¨ller glia. IFN-γ and IL6
could play a role in microglia mediated activation of Mu¨ller glia, following exposure
to BMP7. We also assessed the role of the Hippo/YAP pathway in the regulation of
xv
gliosis in the retina. We demonstrated that YAP was localized to the nucleus of the
Mu¨ller cells of the retina and was upregulated in IFN-γ induced gliosis in the mouse
retina.
11. INTRODUCTION
1.1 Mammalian retina
The retina is a highly organized neural tissue located at the back of the eye which
converts light to an electrical impulse giving us vision [1]. The mature mammalian
retina is organized into three nuclear layers, separated by two plexiform layers made
up synapses of the neurons from adjacent layers. The nuclear layers are: the outer
nuclear layer, made up of the rod and cone photoreceptor cells; the inner nuclear
layer, made up of bipolar, horizontal and amacrine interneurons and the ganglion cell
layer made up of the retinal ganglion cells. Synapses of the photoreceptor cells and
the bipolar cells are found in the outer plexiform layers, while the inner plexiform
layer consists of the synapses between the bipolar cells and the retinal ganglion cells.
The axons of the ganglion cells form the nerve fiber layer and exit the retina through
the optic nerve, carrying the signal to the brain. The Mu¨ller glia, which are the pri-
mary glial or non-neural support cells, are found in the inner nuclear layer with the
processes extending the length of the retina. The retina also consists of the retinal
astrocytes, found in the nerve fiber layer and ganglion cell layer. The microglia, which
are the resident macrophages, are distributed throughout the retina (Figure 1.1) [2].
The photoreceptor cells include the rod and the cone cells. The rod cells are greater
in number in comparison to the cone cells and are involved in providing vision in
situations of dim light and are particularly good for detecting motion. In contrast
the cones are active in bright light and help in object and color recognition, and shape
analysis. There are at least three different types of cone cells identified in human and
non-human primate retinas, classified as short, medium and long wavelength cones,
which aid in color discrimination. Rods outnumber the cones 97:1 in primates and
2Fig. 1.1. Vertebrate eye and the retina. (A) Structure of the mature
mammalian eye, (B) Organization and cells of the mature mammalian
retina [3].
Fig. 1.2. Photoreceptor cell and light activation. (A) Diagramatic
representation of the structure of rod and cone photoreceptor cells,
(B) Light induced activation of G-protein coupled receptors in pho-
toreceptors which ultimately leads to generation of an impulse [4].
3animal models such as mice. The photoreceptor cells convert light to an electrical
impulse, a process known as phototransduction. Structurally, the photoreceptor cells
consist of an outer segment, containing a stack of membrane discs and an inner seg-
ment linked by a connecting cilium. The outer segments contain all the molecular
phototransduction machinery including, the visual pigment, a G-protein coupled re-
ceptor (GPCR) made up of opsin and cis-retinal. When a photon is absorbed by the
visual pigment, the energy from the photon converts the cis-retinal to trans-retinal.
This induces the pigment to the active metarhodopsin-II form, leading to activation
of the transduction cascade. cGMP gated ion channels are closed as a result of cas-
cade in the outer segment, leading to hyperpolarization of the cell (Figure 1.2). The
light induced signals are transferred to the horizontal cells and bipolar cells through
synapses formed with the synaptic terminal of the photoreceptor cells in the outer
plexiform layer. The bipolar interneurons, along with the amacrine cells synapse with
the ganglion cells in the inner plexiform layer to transmit the signal to the ganglion
cells. The horizontal and amacrine cells of the outer and inner plexiform layers, re-
spectively, help in reducing the noise/background of the input signal [4, 5].
The axons of the retinal ganglion cells exiting the retina through the optic nerve ter-
minate in four regions of the diencephalon: the thalamus, pretectum, hypothalamus
and superior colliculus. Most of the axons terminate in the lateral geniculate nuclei
(LGN) in the thalamus. Axons from here project on to the visual cortex. These
form the retinogeniculostriate pathway which is the primary visual pathway. This
pathway processes most of the input visual stimuli. A small percentage of ganglion
cell axons also project to the pretectum, which regulates the pupillary light reflex,
the hypothalamus which involved in the circadian rhythms of the body and to the
superior colliculus which coordinates head and eye movements (Figure 1.3) [6].
4Fig. 1.3. Projections of the retinal ganglion cells. Diagramatic rep-
resentation of the projections of axons from the ganglion cells which
exit from the retina through the optic nerve, crossover at the optic
chiasm and project onto different regions of the brain [7] .
1.2 Development of the retina
The vertebrate eye develops from the eye field, in the anterior neural plate. This
region is characterized by expression of eye field transcription factors such as Six3,
Six6, Rax, Pax6, Lhx2 and Tbx3. Following formation of the neural tube, sonic
hedgehog (SHH) induces the eye field to split, forming the optic grooves. These optic
grooves evaginate to form the optic vesicles, which come into close proximity with
the overlying head ectoderm. Reciprocal signaling between the optic vesicle and the
overlying ectoderm induces the formation of the lens placode from the ectoderm,
which ultimately become the lens [8]. The proximal part of the vesicle forms the
optic stalk, through which the optic nerve exits the eye sending signals to the brain.
The layer close to the lens placode differentiates to form the neural retina, while
the distal part of the vesicle gives rise to the retinal pigmented epithelium [9]. The
retinal progenitors undergo symmetric and asymmetric divisions to give rise of the
different cell types of the retina. The retinal cell types are derived in a sequential
5manner with the retinal ganglion cells being the first born cells. The horizontal cell,
cone photoreceptors and the amacrine cells differentiate in the next wave, while the
bipolar cells, the rod photoreceptors and the Mu¨ller glia differentiate last from the
retinal progenitors (Figure 1.4) [10].
1.3 Retinal glia
The glial cells are the non-neural support cells found in the neural tissue. Broadly,
they can be classified into macroglia and microglia. The retinal macroglia consist
of two cell populations: the Mu¨ller glia, which are the primary glial cell type of the
retina, and the retinal astrocytes. The Mu¨ller cell bodies are found in the inner nu-
clear layer, with the processes extending throughout the length of the retina, from the
inner limiting membrane near the vitreal edge to the outer limiting membrane just
beneath the inner and outer segments of the rods and cones. The retinal astrocytes
are found in the nerve fiber layer [11].
The Mu¨ller glia arise from multipotent retinal progenitor cells. The retinal progeni-
tor cells give rise to ganglion cells first followed by horizontal cell, cone photoreceptor
cells and amacrine cells. The Mu¨ller glial cells are one of the last group of cells that
differentiate from these progenitor cells along with the rod photoreceptors and the
bipolar cells [8]. The retinal astrocytes originate in the optic nerve from glia restricted
precursors. The astrocytes migrate into the retina through the optic disc and move
into the nerve fiber layer [12, 13]. The Mu¨ller glia exhibit a radial glia like morphol-
ogy with their cell bodies in the inner nuclear layer and their processes spanning
the entire retina contacting neighboring neurons. In contrast, the retinal astrocytes
exhibit a stellate morphology, and are found in the nerve fiber layer and ganglion
cell layer [8]. Both the macroglial cell types perform similar functions in supporting
and protecting the retina as listed in the sections below. The microglial cells are
6Fig. 1.4. Development of the vertebrate eye. (A) Neural plate, (B)
Formation of the neural tube, (C) Splitting of the eye field to gener-
ate optic grooves, (D) Evagination of the optic grooves towards head
ectoderm, (E) Closure of the neural tube bringing the optic grooves
in close proximity to the head ectoderm, (F) Formation of the optic
cup and the lens placode, and (G) Region of the optic cup proximal to
the lens placode differentiates into the retina, while the distal portion
gives rise to the retinal pigmented epithelium [10].
7derived from embryonic yolk sac blood islands and migrate into the optic cup early in
development [14]. In addition some vertebrate retinas contain oligodendrocytes that
myelinate the retinal ganglion cell axons in the nerve fiber layer; however the murine
retina does not contain oligodendrocytes [15]. The avian retina also contains a novel
glial cell type termed the non-astrocytic inner retinal glia (NIRG) [16].
1.4 Retinal glial functions
The retinal glia play an important role in maintaining retinal homeostasis and sup-
porting normal function of the neurons. They are required for neuronal survival as
well as serve as a conduit for exchange of molecules [17]. Broadly, they play a role in
regulating the neurotransmitter uptake, releasing factors for neuronal survival, pro-
tecting the neurons from oxidative stress, formation and maintenance of the blood
retinal barrier, as well as regulating water and ion homeostasis (Figure 1.5).
1.4.1 Regulating glucose metabolism
The brain utilizes 25% of the glucose present in the human body, most of which is
utilized due to neuronal activity [18]. The neurons are reliant on external sources,
particularly the glial cells, for the supply of nutrients for the oxidative metabolism.
Furthermore, the glial cells also store excess glucose in the form of glycogen to meet
neuronal demands during increased neuronal metabolic rates. Enzymes involved in
glycogen metabolism such as glycogen synthase kinase 3β and glycogen phosphory-
lase have been shown to be localized to the retinal glia. Studies have shown that
the Mu¨ller glia convert excess glucose to glycogen in an insulin dependent manner
(PerezLeon et al. 2013; Pfeiffer-Guglielmi et al. 2005). Glucose uptake in the glial
cells is mediated by the glucose transporter 1 (GLUT 1) receptor. Most of the glu-
cose consumed is converted to lactate and released into the extracellular space via the
8Fig. 1.5. Functions of the Mu¨ller glia. The Mu¨ller glia play a role
in support and maintenance of normal neuronal function as well as
establishing the blood retinal barrier, secreting growth factors, energy
storage, neurotransmitter recycling and water and ion homeostasis [3].
9monocarboxylase transporter 2 (MCT2), which is then taken up by the surrounding
neurons [19].
1.4.2 Regulation of glutamate metabolism
Glutamate is the most prominent neurotransmitter released by the photoreceptors,
bipolar and ganglion cells of the retina. The Mu¨ller glia and astrocytes are involved in
removal of the excess glutamate from the extracellular sites via the excitatory amino
acid transporters (EAAT1 – 5) [20]. The major glutamate transporter of the Mu¨ller
cells however, is the glutamate aspartate transporter (GLAST/EAAT1). After its
uptake, glutamate is rapidly metabolized by the enzyme glutamine synthetase to glu-
tamine or utilized for the production of glutathione, an antioxidant. Glutathione is
localized to the retinal glia, and only released under conditions associated with ox-
idative stress. Glutamine synthetase is localized throughout the cytosol of the Mu¨ller
glia and astrocytes in the retina. The glutamine produced by Mu¨ller glia is released
and taken up by neurons for synthesis of glutamate and gamma aminobutyric acid
(GABA) [21]. Bipolar cells and ganglion cells are highly dependent on glutamine
from the Mu¨ller glia as revealed by studies inhibiting glutamine synthetase [22]. The
transport and uptake of glutamine from the glia to the neurons is mediated by neu-
tral amino acid carrier systems A and L (ATA and LAT); and the sodium dependent
amino acid exchanger (ASCT2) [21].
1.4.3 Synaptic function
The processes of the macroglia have been found to be in close association with the
synaptic region of retinal neurons. They have been shown to promote synapse forma-
tion in vitro [23]. Furthermore, it is thought energy substrates, neurotransmitter pre-
cursors, ions and neurotrophic factors such as glial cell line derived neurotrophic fac-
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tor (GDNF), released by the glial cells help in maintaining normal synaptic function
(Pfrieger and Barres 1996). Furthermore, macroglia have been thought to be directly
involved in regulating synaptic signaling via release of gliotransmitters (GABA, ATP,
glutamate). The processes of the glial cells involved in the modulation of synapse
are hypothesized to form a tripartite synapse with the pre and post synaptic termi-
nals [24].
1.4.4 Development and maintenance of blood retinal barrier
The blood retinal barrier is a physical barrier that separates the circulating blood
and the extra cellular fluid in the retina. This barrier makes the retina an immune
privileged site and also regulates the chemical environment within the tissue. In the
retina, the blood retinal barrier (BRB) consists of the outer barrier, formed by the
retinal pigmented epithelium, and the inner barrier, formed by the endfeet of the
retinal glia and cells of the retinal vasculature [25]. The inner barrier is formed by
the tight junctions between adjacent endothelial cells, stabilized by pericytes and the
covered by the macroglia endfeet. These tight junctions regulate the movement of
fluids and other substances between the blood and the retina. The Mu¨ller glia secrete
factors such as pigment epithelium derived factor (PEDF) and GDNF which enhance
the barrier function of the retina [26].
1.4.5 Maintenance of ion homeostasis in the retina
Mu¨ller glia help maintain homeostasis by regulating extracellular pH, Na+, K+ ions,
and water. The Mu¨ller glia express inwardly rectifying potassium (Kir) channels
through which they regulate the extracellular potassium concentrations. The Kir 4.1
channel, localized to the vitreal endfeet and perivascular membrane, and the Kir 2.1,
distributed throughout the Mu¨ller glia, are the two main types of the Kir channels
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involved in potassium regulation [27]. They take up the excess ions released at the
synapses by neurons and transport it to the blood or the vitreous through these chan-
nels [28]. The Mu¨ller glia also express the glial water channel, aquaporin-4 (AQP4),
expressed primarily in the perivascular membrane and endfeet [29]. The Mu¨ller glia
also help regulate the CO2 and pH by the action of carbonic anhydrase and acid/base
transporters present at the endfeet. The glia specific enzyme, carbonic anhydrase,
transfers the CO2, a by-product of metabolic activity in the neurons, to HCO3− and
also generates a proton. The HCO3− is redistributed via the H+/HCO3− exchanger
into the perivascular membrane or the blood vessels [17,30].
1.5 Microglia
The microglia are the resident macrophages of the retina, migrating within the retina
to clear cellular debris and surveying the microenvironment. The microglia are found
in the nerve fiber, ganglion and inner plexiform layers, while deeper microglia lie
within the outer plexiform layer (Figure 1.6). The microglial cells appear to be orig-
inating from the embryonic yolk sac blood islands and migrate into the very early
developing brain, suggesting that these may be present in the optic pits prior to
closure of the neural tube and development of the optic cups [14].These resting or
ramified microglia have highly motile processes which scavenge their local surround-
ings for cellular debris and various other metabolic products and phagocytose these
substances [31]. They have also been found to be important regulators of neuronal
differentiation as well as synapse modification [32]. The microglial cells play an impor-
tant role in immune and inflammatory response in the retina. They express receptors
such as toll like receptors, scavenger receptors, cytokine and chemokine receptors, as
well as MHC receptors. Expression of receptors such as the toll like receptors me-
diates their response to lipopolysaccharide, bacteria and viruses. They also express
fractalkine receptors CX3CR and CCR which are required for normal physiological
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functions. Activation of these receptors due to invading pathogens or neuronal injury
mediates the release of chemokines, cytokines and other inflammatory factors [33].
Fig. 1.6. Functions of microglia. Resting microglia constantly survey
their surroundings and are involved in debris removal via phagocy-
tosis, secretion of neurotrophic factors and secretion of neurotrophic
factors as well as mediating synaptic remodeling [24].
During development the microglia have been shown to play a role in neuronal survival
by secreting factors such as insulin like growth factor-1 (IGF-1), phagocytosis of im-
mature/degenerating ganglion cells via the activation of triggering receptor expressed
on myeloid cells-2 (TREM2) or fractalkine signaling, and in synaptic pruning [34–37].
Evidence suggests that the microglia, in addition to the macroglia, play a role in an-
giogenesis. Microglial cells have been shown to recognize the capillary forming tip
cells, and subsequently aid in branching and new vessel formation. While mice lack-
ing microglia did show decreased vascular branching in the retina and CNS during
development, the vasculature recovered as development progressed indicating the mi-
croglia facilitated, but are not essential to branching [38]. Alternately, injection of
microglia in damaged retinas has been shown to promote vascular repair [39]. Mi-
croglia are a highly dynamic cell. In their resting state, confocal microscopy has
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revealed their processes to be in constant motion, surveying the surroundings. This
constant surveillance of the surrounding environment is aimed at maintaining home-
ostasis through absorption of cellular debris, uptake of excess neurotransmitter, and
regulating synaptic activity [40].
1.6 Reactive gliosis
Reactive gliosis is a stereotypical response characteristic of astrocytes and Mu¨ller glial
cells following injury or during disease that is accompanied by loss of function, growth
factor expression, hypertrophy, extracellular matrix remodeling, de-differentiation,
and proliferation (Figure 1.7). Reactive glia are observed in many states of central
nervous system (CNS) injury such as ischemia, trauma, hypoxia and neurodegenera-
tive diseases such as Alzheimers disease [41]. In the eye, retinal gliosis is observed in
all forms of retinal injury or disease such as glaucoma, diabetic retinopathy, photic
damage, ischemia and retinal trauma [42].
The hallmark of reactive gliosis is hypertrophy due to increase in the intermediate fil-
ament glial fibrillary acidic protein (GFAP). Protective and regenerative responses of
astrocytes and Mu¨ller glia involve, among others, the production of neurotrophic fac-
tors, the release of antioxidant agents, the uptake of excess glutamate, the restoration
of the bloodbrain barrier, the promotion of neovascularization and remyelination, and
the support of axonal regeneration and synaptic remodeling. These responses from
the glial cells can be described by a wide range of molecular changes in the glial
cells. These include regulation of intermediate filaments such as vimentin and GFAP;
extracellular matrix molecules such as chondroitin sulfate proteoglycans (CSPGs)
and matrix metalloproteinases (MMPs); enzymes regulating oxidative stress such as
nitric oxide synthase; growth factor production; calcium binding proteins such as
S100β; glial components involved in neurotransmitter regulation such as glutamine
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Fig. 1.7. Reactive gliosis in the Mu¨ller glia. Damage/loss of neurons
due to an injury or disease induces Mu¨ller glia to undergo molecular
and functional changes, a response classified as reactive gliosis or ac-
tivation. In mild injuries, the changes in the Mu¨ller glia are transient
and the cells revert back to the normal/resting stage upon removal of
the stimulus. In severe injuries, the cells also undergo proliferation,
de-differentiation and mediate changes to the extra cellular matrix
leading to formation of a glial scar. They also secrete factors which
can exacerbate the damage/loss to retinal neurons [3].
synthetase and EAAT; inflammatory regulators such as cytokines; molecules involved
in fluid and ion homeostasis such as aquaporins and Kir channels; and transcriptional
regulators such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) and SMADs. These changes are stimulus dependent and response observed may
be any combination of the above changes [43, 44].
Gliosis is an injury dependent response and in cases of widespread damage, glial cells
can also remodel the extracellular matrix leading to the formation of a glial scar.
The glial scar is a physical barrier which permanently sequesters the injured tissue
from neighboring healthy tissue, as well as secretion of factors which can prevent
axon regeneration [41, 45]. They also secrete inflammatory factors such as tumor
necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β) and IL-6, which can lead to
chronic inflammation via microglia activation, and can further exacerbate the gliosis
response [46,47]. Further, increased Mu¨ller cell proliferation in severe or chronic reti-
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nal damage leads to loss of its functional properties, for example due to reduction of
Kir channels, which could be detrimental to the neuronal function and survival [48].
A very small percentage of reactive Mu¨ller glial cells have also been shown to re-enter
the cell cycle, become proliferative and express progenitor markers under certain con-
ditions [49].
The initial gliosis response of macroglia is essential to protect the neurons from fur-
ther damage. Release of neurotrophic factors such as leukemia inhibitory factor (LIF)
and ciliary neurotrophic factor (CNTF), antioxidants such as glutathione, uptake of
excess glutamate and release of nitric oxide serve to increase neuronal survival and
prevent oxidative and excitotxic damage to the neurons. Secretion of inflammatory
cytokines and chemokines serve to attract microglia to the site of injury to aid in
phagocytosis of cellular debris, thereby, indirectly protecting the retinal tissue. How-
ever, at the later stages or if the injury is more severe, gliosis becomes detrimental to
retinal tissue. As previously stated, severe gliosis can lead to formation of a glial scar
and increased production of inflammatory factors. Prolonged expression of factors
such as vascular endothelial growth factor (VEGF), inflammatory markers and NO,
which initially serve to be protective, now lead to detrimental effects on the neurons.
Excessive VEGF can lead to vascular leakage and neovascularization. While low con-
centrations of nitric oxide (NO) protect the neurons against glutamate excitotxicity,
increased NO production can lead to oxidative damage of neurons [45, 50]. In this
state, some Mu¨ller cells also undergo proliferation and de-differentiation. This leads
to loss of supportive functions such as reduced glutamate, ion and water uptake, in-
creasing the susceptibility of neurons to damage [51].
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1.7 Microglia activation
Microglia in response to pathogen invasion, tissue damage, disease or injury undergo
a change in the morphology as well a change in expression of various markers. This
response is termed microglial activation. Microglial activation is observed in many
retinal diseases including retinitis pigmentosa, glaucoma, age related macular degen-
eration and in diabetic retinopathy, to name a few. The activated microglia change
from a ramified morphology to a more amoeboid shape, exhibit enhanced prolifera-
tion and migration (Figure 1.8). Primarily, active microglia exhibit increased levels
of cytokine such as TNF-α, interferon gamma (IFN-γ), interleukins, chemokines such
as chemokine ligand 2 (CCL2 or monocyte chemoattractant protein 1 MCP1), CCL5
(RANTES) and growth factors such as macrophage colony stimulating growth fac-
tor (M-CSF/CSF), granulocyte macrophage colony stimulating factor (GM-CSF) and
transforming growth factor-beta1 (TGF-β1) [52–54].
Expression of these factors serves to aid in migration of the microglia to the tis-
sue damage site as well as induce the inflammatory response. Depending on the
expression of markers, the activated microglia are further classified into the classi-
cally activated M1 phenotype or the alternatively activated M2 phenotype. The M1
phenotype is characterized as the response of microglia resulting in: upregulation
of primarily pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, increased
production of reactive oxygen species and upregulation MHC proteins to serve as
antigen presentation cells [55]. The M2 phenotype, however, is primarily ascribed to
the tissue repair and anti-inflammatory function of the microglia. Upregulation of
anti-inflammatory cytokines such as IL-10, IL-18, extracellular matrix proteins such
as YM1, ornithine to promote wound repair and receptors such as TREM2 which
aides in debris clearance [56].
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Fig. 1.8. Changes in microglia following activation. Diagramatic
representation of changes to the microglia following activation. Mi-
croglia can be activated into a pro-inflammatory M1 state or an anti-
inflammatory M2 state [24].
1.8 Mu¨ller glia and microglia interaction in the retina
Reactive gliosis and microglia activation are responses seen in the retina in various
disease and injury models. Furthermore, studies characterizing the glial responses
have revealed close association between the two cell types. For example, in the nor-
mal retina, microglia morphology and motility of the processes regulated by ATP
released from the Mu¨ller glia, which in turn is regulated by extracellular glutamate
levels [57, 58]. These signals thus, constitute a mode of communication between the
Mu¨ller glia and the resting microglia in the normal retina. Similarly in the injured
retina, signals from activated microglia can potentially affect the state of the Mu¨ller
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glia, and vice versa. Wang et al., 2011 showed Mu¨ller cells respond to microglia acti-
vated through exposure to lipopolysaccharide (LPS), increased expression of neuron
survival factors such as GDNF and LIF [59]. These cells also increased expression
of inflammatory markers such as IL-1β and IL-6, which in turn was able to able to
activate resting microglia. Similarly, in a study modeling neurodegeneration in vitro,
astrocytes were showed to be essential for microglial activation [60].
Factors such as TNF-α, inducible nitric oxide synthase (iNOS), IL-1β have been iden-
tified as potential factors which could be playing a role in the interaction between the
two glial populations [61]. While microglia derived factors have been shown to trigger
gliosis in the macroglia, the pro-inflammatory factors derived from astrocytes/Mu¨ller
glia could contribute to the chronically active microglia, which can cause further
damage to the neural tissue [62]. Furthermore, changes to the extracellular matrix by
reactive macroglia can also trigger activation of microglia leading to a prolonged in-
flammatory response, which is detrimental [63]. However, astrocytes have been shown
to negatively regulate microglia activation through TGF-β signaling by downregulat-
ing expression of pro-inflammatory cytokines and antigen presentation markers [64].
1.9 Factors in gliosis
Many factors have been identified which could trigger reactive gliosis including re-
active oxygen species, hypoxia, growth factors such as CNTF and LIF; and factors
associated with inflammatory response such as TNF-α and IFN-γ (Figure 1.9) [3].
The breakdown of the blood retinal barrier (BRB), observed in most of the retinal
diseases, has been determined to be the major cause for loss of vision and reactive
gliosis. Oxidative stress, hypoxic and hyperglycemic conditions in diabetic retinopa-
thy, glaucoma, AMD, retinitis pigmentosa (RP) etc. lead to breakdown of the BRB,
which in turn cause an upregulation of inflammatory cytokines and chemokines, as
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well as factors such as CNTF, LIF and vascular endothelial growth factor (VEGF).
These signals regulate gliosis either on their own or in combination with other factors.
Fig. 1.9. Known factors regulating gliosis. Gliosis has been described
in all retinal injuries and disease conditions. Factors which trigger
gliosis include: mechanical injury, an increase in inflammatory mark-
ers, reactive oxygen species as well as factors such as CNTF [65].
TNF-α has been shown to upregulate GFAP expression in astrocytes through mi-
togen associated protein kinase (MAPK) signaling [66, 67]. It has also been shown
to upregulate expression of other inflammatory cytokines such as IL-1β, IFN-γ and
TNF-α, from the glial cells [59]. Similarly, IFN-γ and IL-1β have been shown to reg-
ulate expression of inflammatory cytokines as well as GFAP levels in the macroglia.
CNTF regulates a wide range of gliosis markers in astrocytes and Mu¨ller glia primar-
ily via the janus kinase-signal transducer and activator of transcription (JAK-STAT)
pathway. These include growth factors and cytokines such as TGF-β and TNF-α,
GFAP and other genes such as S100β, lipocalin-2 and ion channels, previously shown
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to be regulated in gliosis [68]. Fischer et al., 2004 demonstrated the effect of different
factors on retinal gliosis in the chick retina. While CNTF induced an upregulation of
GFAP in the Mu¨ller glia, FGF2 induced vimentin upregulation [69]. In the zebrafish
retina, IL-6 has been shown to induce proliferation of Mu¨ller glia via the JAK-STAT
pathway [70]. Platelet derived growth factor (PDGF) has also been shown to in-
fluence retinal macroglia. Yamada et al., 2000 demonstrated that PDGFA induced
astrocyte migration, GFAP upregulation as well release of factors such as insulin like
growth factor (IGF) and VEGF in the macroglia [71]. TGF-β, another factor regu-
lated during gliosis has been shown to influence the extracellular matrix composition,
inducing expression of chondroitin sulphate proteoglycans (CSPGs) via the SMAD
independent AKT-mTOR pathway [72].
1.10 Bone morphogenetic proteins (BMP) in the retina
The BMPs consist of a large number of signaling molecules belonging to the TGF-β
superfamily. The BMP ligands signal primarily by forming homo- or hetero-dimers,
which then bind to the receptor associated proteins. The BMP receptors are serine
threonine kinase receptors, classified into 2 groups: the type I and type II receptors.
The BMP type I receptors act downstream of the type II receptors and determine the
specificity of the signal. Three type I (Alk -2, -3 and -6) and type II (BMPRII, ActR
II A and ActR II B) receptors have been identified which bind BMP ligands. While
the BMP ligands have specificity to certain receptors, for example Alk1 for BMP9
and Alk2 for BMP7, they bind with lower affinity to other receptors and mediate
their downstream pathways [73]. Binding of the ligand leads to phosphorylation and
activation of the receptors, which then phosphorylate the receptor-bound signaling
mediators (Figure 1.10). The BMPs signal canonically via the SMAD pathway and
non-canonically via the TAB-TAK pathway or FRAP-STAT pathway. Binding of
ligand to the receptor leads to activation of the bound mediators: SMADs (SMAD
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-1, -5 and -8), x-linked inhibitor of apoptosis (XIAP) protein and the immunophilin
FKBP12. Upon BMP activation, the SMADs are phosphorylated and dimerize with
SMAD4, and are then translocated to the nucleus to bind to specific sequences in the
DNA, bringing about transcriptional regulation of target genes. XIAP leads to the
formation of a XIAP-TAB1-TAK1 complex, activating the MAPK pathway, while
phosphorylation of the FKBP12 protein activates the FRAP (FKBP12 rapamycin
associated protein) molecule which then activates and phosphorylates STAT leading
to transcriptional regulation [74,75].
Spinal cord and retinal injury models have shown an upregulation of BMPs (4 and
7) at the injury site, as well as an increase in phospho SMAD 1/5/8 in glial cells in
the retina [77,78]. BMP4 regulates survival of amacrine neurons and proliferation of
Mu¨ller glial cells in a retinal injury model [79]. BMP7 has been found to be neuro-
protective in spinal cord injury models in rats and activation of the SMAD pathway
in murine retinas following injury has been shown to promote the survival of the
ganglion neurons [78,80]. Furthermore, the opposing effect of activation of 2 different
BMP receptors on gliosis has also been determined by Sahni et al,. 2010 [81]. Thus,
the BMPs are implicated to be regulated during gliosis, although the mechanism and
effects are not fully understood. Furthermore, the crosstalk between the downstream
signaling components of the canonical and non-canonical pathways with each other
or other pathways may be involved.
1.11 Hippo pathway and role in gliosis
While gliosis has been universally described in disease and injury states of the central
nervous sustem, it is unclear at this time whether the factors that regulate gliosis act
through a common mechanism to trigger de-differentiation. Part of this dissertation
is directed at the hypothesis that angiomotins and the Hippo pathway may be a com-
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mon mechanism by which external signals trigger de-differentation that accompanies
gliosis. The Hippo pathway is known to be an important regulator of tissue formation
and organogenesis by regulation of proliferation, growth and differentiation. Activa-
tion of upstream regulators, primarily found in apical junction, leads to activation of
the core kinases of the hippo pathway, MST1/2 and Lats1/2 (Figure 1.11). Regulators
of the core kinases of the hippo pathway include apical and basal junction proteins
such as neurofibromatosis 2 (NF2), scribble and crumbs, as well as proteins associ-
ated with the cytoskeleton such as E-cadherin, α-catenin and angiomotins (AMOT),
growth factors such as EGF and G-protein coupled receptors [82,83]. When activated,
these regulators activate MST kinases which in turn activate the LATs kinases. The
activated core kinases phosphorylate the yes activated protein (YAP) and leads to
its cytoplasmic localization. In the unphosphorylated state, YAP is localized to the
nucleus, and along with co regulator transcriptional co-activator with PDZ-binding
motif (TAZ). Within the nucleus, it binds with the transcription factor transcriptional
enhancer associate domain (TEAD) and brings about regulation of target genes in
the cell [84]. The YAP/TAZ complex has also been shown to bind to other tran-
scription factors such as SMAD and RUNX to mediate transcriptional regulation. In
the nucleus, the primary targets of the YAP/TAZ/TEAD complex include growth
promoting and anti-apoptotic genes such as connective tissue growth factor (CTGF),
Sox4, c-Myc and baculoviral IAP repeat containing protein (BIRC), proteins involved
in regulation of cell cycle such as cell division cycle 6 (CDC6), protein c-ets1 (ETS1)
and kinesin family member 23 (KIF23) [85].
As mentioned in the previous section, one of the factors regulating Hippo/YAP path-
way are the AMOTs. The AMOTs were initially identified for their role in endothelial
cell migration and angiogenesis. The AMOTs consist of a PPXY protein interaction
motif and a WW binding motif in the N terminal domain, a coiled-coiled domain
and a C-terminal PDZ binding motif [87]. AMOTs have been shown to interact with
tight junction proteins Merlin and Rich1 to maintain tight junction integrity [88].
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Fig. 1.11. Hippo pathway and its regulation. (A) Hippo pathway
cascade is mediated by a core of kinases (MST1 and LATs1) which
phosphorylate YAP. When hippo pathway is turned on, YAP is
phosphorylated and sequestered to the nucleus and in the absence
of signal, the unphosphorylated YAP translocates to the nucleus
regulating target genes by binding to the TEAD co-factor. (B) The
Hippo pathway is regulated angiomotins, extra-cellular matrix, stress
signals and G-protein coupled receptors [86].
The AMOTs also interact with YAP via the PPXY motif to sequester YAP to the
cytoplasm and inhibiting it. Furthermore, AMOTs can also inhibit YAP by activat-
ing LATs and MST through an unknown mechanism, which can phosphorylate and
inhibit YAP [86].
Research has shown that Hippo pathway components are involved in cross talk with
other signaling pathways including the Wnt pathway, TGF-β/BMP pathway, EGF
signaling and Notch signaling [84, 89]. YAP/TAZ complex can inhibit and promote
Wnt signaling. Cytoplasmic YAP/TAZ sequester β-catenin and SHP2 to the cyto-
plasm due to phosphorylation, thereby, inhibiting Wnt signaling [90, 91]. However,
Xin et al,. 2011 showed that nuclear YAP can upregulate IGF signaling which in
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turn leads to activation of β-catenin and the Wnt pathway [92]. Alcaron et al,. 2009
showed YAP mediated SMAD regulation of transcription activity in mouse embryo
development [93]. Furthermore, BMP4 and TGF-β are known targets of YAP/TAZ
complex. Similarly, YAP/TAZ/TEAD complex also regulates notch signaling by up-
regulating transcription of Jag1, Notch 2 and Sox9 [94]. Thus, the hippo pathway
appears to be a key regulator of cellular homeostasis and has the potential to regulate
multiple pathways in the cell.
The aim of this dissertation is to expand the understanding of retinal gliosis by ad-
dressing the following hypothesis: BMP7 triggers a response gliosis in the retina by
regulating activation of the glial cells. We further propose that regulation of the
Hippo pathway during gliosis may be a common pathway that links this response
following different stimuli and that it mediates the de-differentiation response of the
Mu¨ller glia. We propose to address these questions through the following aims: 1)
Determining the effect of BMP7 on the retinal macroglia, 2) Determining the effect
of BMP7 on the microglia and potential cros-talk with the macroglia, and 3) Deter-
mining the regulation of the Hippo/YAP signaling in retinal gliosis.
26
2. BONE MORPHOGENETIC PROTEIN 7 REGULATES
REACTIVE GLIOSIS IN RETINA ASTROCYTES AND
MU¨LLER GLIA
2.1 Introduction
The mature mammalian retina contains several types of macroglial cells; Mu¨ller glia,
retinal astrocytes, and, in some cases oligodendrocytes and non-astrocytic retinal glial
cells (NIRG) [95–97]. The Mu¨ller glia arise from neural retinal progenitor cells late
in retinal development. The Mu¨ller cells span nearly the entire width of the retina
from the outer limiting membrane, where Mu¨ller processes form connections with
photoreceptors, to the inner limiting membrane where Mu¨ller and retinal astrocyte
processes form the boundary between the retina and the vitreous [17]. The retinal
astrocytes migrate into the retina from the developing optic nerve and their cell bod-
ies populate the nerve fiber layer and send processes into the ganglion cell layer [13].
While the NIRG cell origins are unknown, they have been hypothesized to migrate
from the developing optic nerve [96]. Both the Mu¨ller glia and retinal astrocytes have
been shown to play very important roles in supporting and protecting the retinal
neurons. For instance, both are critical to the formation of the blood-retinal barrier,
neurotransmitter recycling, removal of toxins, and growth factor supplementation of
ganglion cells [11, 46,98–100].
An important property of the glial cells is their response to any damage/injury to
nearby neurons; a response known as reactive gliosis. The Mu¨ller glia and, retinal,
and optic nerve astrocytes become reactive in various disease states such as glau-
coma, retinal ischemia, and diabetes [50, 101]. One particularly interesting aspect of
gliosis is the molecular diversity in the reaction of the macroglia to various disease
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states and injuries [44, 69, 102]. For instance, insult-dependent increase or decreases
in the expression of glial fibrillary acidic protein (GFAP), vimentin, glutamine syn-
thetase (GS), and extracellular matrix molecules (ECM) have been noted in Mu¨ller
glial cells and/or astrocytes [50, 103–105]. This variance has been hypothesized to
be the result of the release of various factors that drive different aspects of reactive
gliosis [43, 69, 106]. Further diversity in the response is introduced by virtue of the
fact that reactive astrocytes fall on a continuum from mild to severe, in which cells
display one or more of the following; hypertrophy, de-differentiation, loss of function,
proliferation, inflammation, and remodeling of the tissue and vasculature [3, 107].
Furthermore, some of the cellular responses are dual in nature. An example of this
is the hypertrophy of Mu¨ller glia and astrocytes that results from an increase in the
intermediate filaments GFAP and vimentin. On one hand the hypertrophied cellular
processes may form a barrier around the injured region, inhibiting the spread of in-
flammatory molecules into healthy tissue; on the other hand, these processes can also
block the regeneration of axons and synapses [107].
Severe reactive gliosis is also accompanied by tissue remodeling that includes ex-
cessive hypertrophy of the glial cell bodies and processes as well as the turnover of
the extracellular matrix to a regeneration-inhibitory matrix, together referred to as
a glial scar. One of the major components of the ECM are the chondroitin sul-
fate proteoglycans (CSPGs), a family of molecules that includes neurocan (NCAN),
phosphacan (PCAN), versican, aggrecan, brevican, nerve/glial antigen 2 (NG2), and
CD44 [108]. Although the mechanisms and triggers have not been completely char-
acterized, a variety of growth factor signaling mechanisms are found to be important
in reactive gliosis such as epidermal growth factor (EGF), fibroblast growth factor
(FGF), tumor necrosis factor-α (TNF-α), ciliary neurotrophic factor (CNTF), in-
sulin and WNTs [43, 107, 109]. Data from several laboratories have indicated that
each pathway may regulate specific characteristics associated with reactive gliosis.
For instance, CNTF appears to be associated with the upregulation of GFAP, while
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EGF and FGF are associated with proliferation [104, 110]. Studies using different
CNS injury models have shown that the BMP pathway is upregulated at the site of
injury in the CNS and can trigger reactive gliosis [77, 111, 112]. Furthermore, BMP
receptor 1A has been linked to hypertrophy, whereas BMPR1b has been associated
with glial scars [81]. While the BMPs have been associated with penetrating wounds
in the spinal cord, no information is available regarding the role of BMPs within the
retina and in disease states of the CNS.
BMPs interact with two different types of receptors; type I and type II, both of
which are serine-threonine kinases. The type II receptors phosphorylate and activate
the type I receptors, and the type I receptors then can activate several intracellular
pathways. The intracellular pathways are subdivided into different pathways, the
canonical pathway and several non-canonical pathways [75]. The canonical pathway
consists of the activation of receptor SMADs (R-SMADs) 1, 5, and 8 by the type I
BMP receptors. Once activated, the R-SMADs form heterodimers with the co-SMAD,
SMAD4, whereupon they localize to the nucleus to interact with other transcription
factors and regulate gene expression. BMP receptors type IA and IB have also been
shown to activate X-chromosome-linked apoptosis protein (XIAP). XIAP connects
the BMPRIA and IB to the kinase Transforming growth factor -β activated kinase
1 (TAK1), which activates downstream pathway members such as p38, Nuclear fac-
tor kappa light chain enhancer of activated B cells (NFκB), and c-Jun N-terminal
kinases (JNK) [113]. Another non-canonical pathway that has been identified is the
FKBP12/rapamycin associated protein - signal transducer and activator of transcrip-
tion (FRAP-STAT) pathway. Activation of this pathway occurs via phosphorylation
of FK506 rapamycin binding protein (FKBP12) by BMPR IA and/or IB, eventually
leading to the activation of STAT proteins, leading to changes in transcription [74].
In this study, we hypothesized that BMP7 plays a role in initiating reactive gliosis
in glial cells of the retina. As a first step, we characterized the BMP receptors and
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intracellular signaling molecules present in the Mu¨ller glial cells of normal adult unin-
jured retina. Using in vitro systems, we observed differential regulation of molecules
typically associated with reactive gliosis in retinal astrocytes and human Mu¨ller glial
cells following treatment with BMP7. Both retinal astrocytes and MIO-M1 Mu¨ller
cells showed modest increased Gfap and Pax2 levels following treatment with BMP7,
but only retinal astrocytes appeared to show changes in matrix metalloproteinases
(Mmps) and CSPGs. In contrast, addition of BMP4 in vitro appeared not to lead to
reactive gliosis in either retinal astrocytes or MIO-M1 Mu¨ller glial cells. Injection of
BMP7 into the mature mouse eye led to more robust increases in molecules associated
with reactive gliosis, such as Gfap, Pax2, Mmps, and CSPGs Ncan and Pcan. These
results are consistent with the hypothesis that BMP7 acts as a trigger for reactive
gliosis in disease states in the eye.
2.2 Materials and methods
2.2.1 Tissue Processing and Fluorescent Immunohistochemistry
Eyes from C57BL/6J (Jackson Laboratories, Bar Harbor, ME) were dissected from
the heads of euthanized animals, washed in phosphate buffer saline (PBS; 40mM
K2HPO4, 123.2mM NaCl, 8.4mM NaH2PO4; Fisher Scientific, Pittsburgh, PA), and
fixed in 4% paraformaldehyde (Fisher Scientific) for immunohistochemistry. The eyes
were then incubated in an ascending series of sucrose (Fisher Scientific) (5%, 10%,
15% and 20%) made in 0.1M phosphate buffer, pH 7.4 overnight. The tissues were
frozen in a 3:1 20% sucrose-in phosphate buffer and OCT solution (Sakura Finetek
Inc., Torrance, CA). Thick sections (10 µm) were cut using a Leica CM3050 S cryo-
stat and placed on Superfrost Plus slide (Fisher Scientific) treated with Vectabond
(Vector Labs, Burlingame, CA), and were stored at -80◦C until used for immunohis-
tochemistry. Antibodies used for immunohistochemistry are listed in Table 2.1.
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For immunohistochemistry, sections were fixed with 4% paraformaldehyde for 30 min.
Sections were then washed in 1X PBS, permeabilized in methanol (Fisher Scientific)
and subjected to antigen retrieval by placing the sections in 1% SDS (Fisher Scien-
tific) in 0.01 M PBS for 5 min. To aid in autofluorescence reduction, sections were
treated with 1% sodium borohydride in PBS (Fisher Scientific) for 2 min at room
temperature, then rinsed with PBS. Tissue was blocked by incubating with 10%
serum in 1X PBS containing 0.25% Triton X-100 (Bio-Rad, Hercules, CA) at room
temperature for 1 h and incubated with the primary antibody, diluted in 0.025%
TritonX-100 PBS with 2% blocking serum, overnight at 4◦C. The following day, the
slides were incubated in Dylight conjugated secondary antibody (Jackson Immunore-
search, West Grove, PA) at 1:800 diluted with 1X PBS, for 1 h at room temperature,
then washed twice with 1X PBS for 5 min each rinse, and mounted with ProLong
Gold with DAPI (Invitrogen, Grand Island, NY) or counterstained with Hoechst so-
lution (diluted 1:500 in 1X PBS; Sigma-Aldrich, St. Louis, MO) and mounted with
AquaPoly/Mount (Polysciences, Warrington, PA).
31
Table 2.1.
List of antibodies used
Antibody Company IHC concen-
tration
Western blot
concentration
ALK2 Genetex 1:250
βTubulin Sigma 1:1000
BMPR1A Abgent 1:50
BMPR1B SantaCruz 1:100
FKBP12 ThermoScientific 1:100
GFAP Dako (poly-
clonal)
1:250
GFAP Dako (mono-
clonal)
1:1000
NEUROCAN R&D 1:100
PAX2 Aviva 1:500
phosphoSMAD
1/5/8
Cell Signaling 1:50
phosphoTAK Abcam 1:500
S100β Abcam 1:300 1:1000
SMAD1 Abcam 1:100
SOX2 SantaCruz 1:250
TAK1 Abcam 1:250
TXNIP SantaCruz 1:250
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For labeling of mouse tissue slides with glutamine synthetase (GS), blocking and
overnight incubation with primary antibody was performed as specified by the Vec-
tor mouse-on-mouse immunodetection kit (Vector Labs). For immunolabeling with
NCAN, SMAD, BMP receptor 1A, 1B and TAK1, biotin streptavidin amplification
was performed. Following overnight incubation with the primary antibody, the sec-
tions were first incubated with biotinylated antibody (1:1000, Vector Labs) for 1 h
and then streptavidin conjugated Dylight (1:33, Vector Labs) for 1 h at room temper-
ature. For colabels of phospho-SMAD1/5/8 and phospho-TAK1 with sex determining
region Y box 2 (SOX2), sections were subjected to heat antigen retrieval following
methanol incubation. Briefly, the sections were incubated in sodium citrate buffer
(10mM sodium citrate; Fisher Scientific, 0.05%Tween 20; Fisher Scientific, pH 6.0)
at 65◦C for 1 h, allowed to cool for 20 min, rinsed 3X in water, 1X in PBS and
blocked with 10% horse serum in 1X PBS containing 0.25% Triton X-100 for 1 h
at room temperature. Following overnight incubation with the primary antibodies,
the slides were incubated with biotinylated horse anti rabbit (1:300, Vector Labs) for
1 h and then Alexa flour anti goat (1:500, Invitrogen) and HRP (1:500, Biolegend,
San Diego, CA) for 1 h. The slides were then washed 2X in TNT buffer (0.1M Tris-
HCl, 0.15M NaCl, 0.05%Tween 20) and incubated with fluorescin plus amplification
reagent diluted 1:300 in 1X tyramide signal amplification (TSA) amplification dilu-
ent (Perkin Elmer, Waltham, MA) for 5 min. The slides were washed 2X in TNT
buffer, 2X in PBS, counterstained with Hoechst solution and mounted with Aqua-
Poly/Mount (Polysciences). Slides were viewed under Olympus Fluoview FV 1000
confocal microscope.
2.2.2 Isolation of RNA and protein
Isolated retinas were processed and used for RT-qPCR and western analysis. Briefly,
animals were euthanized by CO2 exposure. Eyes were then dissected using sterile
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forceps and the retina isolated. The retinas were homogenized and processed for
RNA using RNeasy Mini Kit as per manufacturers protocol (Qiagen, Valencia, CA).
Briefly, isolated retinal tissue or cells were homogenized in buffer RLT. 70% ethanol
was added and the solution centrifuged in a RNeasy spin column. The flow through
was discarded, 700µl of buffer RW1 was added and centrifuged. Following this step,
500µl of buffer RPE was added to the spin column and centrifuged. This step was
repeated once, following which the RNA was eluted with 40µl of RNase free water.
RNA was quantified using NanoDrop 2000c (ThermoScientific, Rockford, IL).
For protein isolation, retinas isolated were homogenized and incubated with radioim-
munoprecipitation assay (RIPA) lysis buffer (0.1%SDS, 50mM Tris-HCl pH 7.5, 1%
Triton-X100) supplemented with 0.01mM phenyl methyl sulfonyl fluoride (PMSF;
Roche Diagnostics, Indianapolis, IN) and 1:25 protease inhibitor cocktail (RPI Corp,
Mount Prospect, IL) for 2 h at 4◦C. The tube was then centrifuged at 13680 g for 20
min at 4◦C and the supernatant aspirated into a new tube.
2.2.3 Cell Isolation, Cytospin, and Immunocytochemistry
Retinal cells were isolated as previously described [114]. Briefly, mouse retinas were
prepared in sterile 0.9% saline. Approximately 200 mg of retinal tissue was incubated
with saline containing 0.4 mg/ml papain (Roche) for 30 min at 37◦C. The tissues were
triturated with a siliconized pipette and dissociated single cells were centrifuged at 500
X g for 10 min. The cells were fixed in 4% paraformaldehyde for 10 min, centrifuged,
and washed with saline. The cells were placed onto a Superfrost Plus slide (Fisher Sci-
entific) treated with Vectabond (Vector Labs) using a Cytospin4 (Thermoscientific)
and stored at -80◦C until used for immunocytochemistry. For immunocytochemistry,
the cells were permeabilized in methanol, incubated with 1% SDS in 0.01M PBS, and
washed in 1X PBS. The slides were then incubated with 1% sodium borohydride,
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blocked using the mouse on mouse kit (Vector Labs), and co-labeled with GS and
the BMP receptor antibodies (BMPR1A, BMPRIB and activin receptor like kinase 2;
ALK2). Following overnight incubation with the primary, the slides were incubated
with the appropriate secondary antibodies with biotin streptavidin amplification used
for the receptor antibodies. The slides were then washed, counterstained with Hoechst
solution, and mounted with Aqua-Poly/Mount (Polysciences).
2.2.4 Cell culture
The mouse retinal astrocytes were isolated as previously stated [115,116]. Cells were
cultured in DMEM (Catalogue # D1152, Sigma-Aldrich, St. Louis, MO) containing
EC growth supplement (Sigma-Aldrich), 1% Pencillin/Streptomycin (Sigma-Aldrich),
1 mM Sodium pyruvate (Life Technologies, Grand Island, NY), 20 mM HEPES
(Sigma-Aldrich), 2 mM Glutamine (Life Technologies), 1x non-essential amino acids
(Sigma-Aldrich), Heparin (Sigma-Aldrich), 10% fetal bovine serum (Atlanta Biochem-
icals, Lawrenceville, GA) and 44U/ml of murine recombinant interferon γ (R & D
systems, Minneapolis, MN). The cells were grown on Cellbind dishes (Fisher Scien-
tific) in an incubator with 5% CO2 at 33
◦C and passaged every 3-4 days using trypsin-
EDTA (Sigma-Aldrich). The human MIO-M1 Mu¨ller glial cell line was obtained from
Dr. GA Limb at the Institute of Ophthalmology, University College London (Limb,
Salt, et al. 2002). MIO-M1 cells were grown in DMEM containing 10% fetal bovine
serum and 200 mM Glutamine (Life Technologies). The cells were grown in sterilized
tissue culture dishes (BD Falcon, Corning, NJ) in an incubator 5% CO2 at 37
◦C and
passaged every 6-7 days using trypsin-EDTA and the medium changed every 3-4 days.
Treatment of retinal astrocytes and MIO-M1 cultures in vitro with sodium peroxyni-
trite (Cayman Chemicals, Ann Arbor, MI) was performed as previously stated [117].
Briefly, confluent astrocyte cell cultures were washed 3 times with phosphate buffer
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saline (PBS) supplemented with 0.8 mM MgCl2, 1 mM CaCl2, and 5 mM glucose.
They were then incubated in 1 ml of 1X PBS (50 mM Na2HPO4, 90 mM NaCl, 5 mM
KCl, 0.8 mM MgCl2, 1 mM CaCl2, and 5 mM glucose, pH 7.4), followed by three
additions of sodium peroxynitrite at a concentration of 0.15 mM. The first bolus of
sodium peroxynitrite was added to one edge of the dish and the buffer was swirled
to allow mixing of the peroxynitrite throughout the dish. This step was repeated
twice while changing the edge at which the addition was made and then incubated
for 5 min. The buffer was then removed, replaced with the respective growth medium
and placed in the appropriate incubators. The cells were then processed after 32 h
for protein or RNA. Some cultures were treated with recombinant BMP7 and BMP4
(R & D systems) reconstituted in 0.4% HCl-PBS. Dishes were treated with either
vehicle or 100 ng/ml of BMP7 or BMP4 for 24 or 36 h. Cells were then processed
for either RNA or protein for analysis via RT-qPCR or Western blotting, respectively.
2.2.5 BMP7 injections in vivo
The mice were injected intravitreally with BMP7 (1 µl of 20 ng/µl). Intravitreal in-
jections were performed with a pump microinjection apparatus (Harvard Apparatus,
Holliston, MA) and pulled glass micropipettes. Each micropipette was calibrated to
deliver 1 µL of vehicle or vehicle containing BMP7. The mice were anesthetized under
a dissecting microscope; the sharpened tip of the micropipette was passed through
the sclera, just behind the limbus, into the vitreous cavity. Once the micropipette
was in place, the vehicle or BMP7 was injected using a PL-1000 picospritzer (Har-
vard Apparatus). D3 or D7 post-injection, the animals were sacrificed and retinas
were dissected for RNA and protein preparations. Each experiment was performed
in triplicate.
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2.2.6 Western blot analysis
Antibodies used for western blot analyses are listed in Table 2.1. The total protein
was quantified using Pierce BCA Protein Assay Kit (ThermoScientific) as per man-
ufacturers protocol. Briefly, 5µl of sample was mixed with 495µl of working reagent
(prepared by mixing Pierce BCA Reagent A and B in 50:1 ratio) and 500µl of water.
This solution was incubated at 65◦C for 30 min, followed by colorimetric analysis
using a NanoDrop 2000c spectrophotometer (Thermscientific). Fifty micrograms of
the total protein mixed with the loading dye (containing 5% β–mercaptoethanol) in
a 3:1 ratio was then loaded and run on a 4-20% SDS polyacrylamide gel (Expedeon,
San Diego, CA) at 125 volts for 1 h. Proteins were transferred to a Polyvinylidene flu-
oride (PVDF) membrane (Bio-Rad) via a wet transfer and subjected to immunoblot-
ting. Prior to incubation with the antibody, the membrane was blocked using a 5%
milk solution in Tris Buffered Saline-Tween (TBST; composition 20mM Tris base,
137mM NaCl, 1M HCl, 0.1% Tween-20, at pH 7.6) for 1 h. The blots were then
incubated with the primary antibody diluted in TBST at 4◦C overnight. The blots
were washed twice with TBST and then incubated with a peroxidase conjugated sec-
ondary antibody (ThermoScientific) diluted to 1:5000 in TBST for 1 h in the dark
at room temperature. The blots were incubated with either Pierce ECL Western
Blotting Substrate (ThermoScientific) or SuperSignal West Femto Chemiluminescent
Substrate (ThermoScientific) and the bands visualized on x-ray films (ThermoScien-
tific). β-TUBULIN was used as a loading control and densitometry of the blots was
performed using the Image J software (http://rsbweb.nih.gov/ij/).
2.2.7 Real Time-Quantitative PCR (RT-qPCR)
Prior to cDNA synthesis, RNA samples were run on a 1% agarose gel to confirm the
overall quality of the total RNA. The cDNA was synthesized from 1 µg of total RNA
with iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturers protocol
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and diluted 1:20 before adding to qPCR wells. RT-qPCR was performed using 7300
RT detection system (Applied Biosystems, Carlsbad, CA) using the Power SYBR
green PCR master mix (Invitrogen, Grand Island, NY). The primer pairs used have
been listed in Table 2.2 (Mouse) and Table 2.3 (Human). Total volume for each
reaction was 20 µl using the diluted cDNA, corresponding to 5ng of initial total RNA
and 0.4mM of each primer. The cycler conditions used were as follows: initial denat-
uration at 95◦C for 10 min, 45 cycles of denaturation at 95◦C for 10 sec, annealing
at 60◦C for 20 sec and extension at 72◦C for 20 sec, followed by a final extension at
72◦C for 5 min.
Efficiency of the primer sets was determined by the standard curve method, where
efficiency, E= ((10(-1/Ct2 Ct1)) 1) X 100. Primer sets with an efficiency between
90% and 110% were used for our experiments. A no template control and an internal
control using primers specific for β 2 Microglobulin (β2M ) were used for each run.
The amplified samples were run on a 2% agarose gel to confirm amplification was of
the right size. The change in the gene expression levels was done using the 2 −δδCt
method, where Ct is the crossing threshold value.
2.2.8 Statistical Analysis
Statistical analysis of RT-qPCR data was by unpaired t-test between the control and
treated groups. Statistical analysis of densitometry results was by students t-test.
All analyses were performed using SPSS software (IBM) and Excel 2010 (Microsoft).
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Table 2.2.
Mouse RT-qPCR primers
Gene Primer Sequence Length (bp)
β2 M Forward TCGCGGTCGCTTCAGTCGTC 135
Reverse CATTCTCCGGTGGGTGGCGTG
Ednrb Forward TTGACCTCCCCATCAACGTG 140
Reverse AGCACAGAGGTTCAAGACGG
Reverse CATTCTCCGGTGGGTGGCGTG
Gal3 Forward GGCGGGTGGAGCACTAATC 74
Reverse TAAGCGAAAAGCTGTCTGCC
Gfap Forward TAGCCCTGGACATCGAGATCGCC 141
Reverse GGTGGCCTTCTGACACGGATTTGG
Glast Forward GATTTGCCCTCCGACCGTAT 185
Reverse ATAGACTACAGCGCGCATCC
Gs Forward GCGCTGCAAGACCCGTACCC 145
Reverse GGGGTCTCGAAACATGGCAACAGG
Kir2.1 Forward GACCCTCCTCGGACCTTACG 151
Reverse ACTGGCCGTTCTTCTTGACA
Lcn2 Forward AATGTCACCTCCATCCTGGTCA 145
Reverse CCACTTGCACATTGTAGCTCT
Mmp9 Forward TGTGCCCTGGAACTCACACGAC 135
Reverse ACGTCGTCCACCTGGTTCACCT
Mmp11 Forward ACTGACTGGCGAGGGGTACCTT 128
Reverse GCAGATGGACCCCATGTTTGCTGT
Mmp14 Forward TGGGCCCAAGGCAGCAACTT 89
Reverse CGTTGTGTGTGGGTACGCAGGT
Ncan Forward CCTGACAAGCGTCCATTCGCCA 90
Reverse ACTGTCCGGTCATTCAGGCCGAT
Pax2 Forward ACCCTGGCAGGAATGGTGCCT 70
Reverse AGGCGGTGTACTGGGGATGGC
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Table 2.2 (Continued)
Gene Primer Sequence Length (bp)
Pcan Forward ATCCCTGAGTGGGGAAGGCACA 96
Reverse AGCAGGGGATGCTGGGTGATGA
S100β Forward GACTGCGCCAAGCCCACACC 142
Reverse TCCAGCTCGGACATCCCGGG
Spp1 Forward TCCTTGCTTGGGTTTGCAGT 188
Reverse GTCACTTTCACCGGGAGGG
Tlr4 Forward TGCCTGACACCAGGAAGCTTGA 102
Reverse AGGAATGTCATCAGGGACTTTGCTG
Timp2 Forward GCAACAGGCGTTTTGCAATG 71
Reverse CGGAATCCACCTCCTTCTCG
Txnip Forward CCTACAGCAGGTGAGAACGA 103
Reverse TAAAGGATGTTCCCAGGGGC
Vim Forward AGGAAGCCGAAAGCACCCTGC 78
Reverse TCCGTTCAAGGTCAAGACGTGCC
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Table 2.3.
Human RT-qPCR primers
Gene Primer Sequence Length (bp)
β2 M Forward AGATGAGTATGCCTGCCGTG 120
Reverse TCATCCAATCCAAATGCGGC
Ednrb Forward TGCTTGCTTCATCCCGTTCA 197
Reverse TCCCGTCTCTGCTTTAGGTG
Egfr Forward AAACAACACCCTGGTCTGGA 126
Reverse GGGATCTTAGGCCCATTCGT
Gal3 Forward GCCTTCCACTTTAACCCACG 74
Reverse TAAGCGAAAAGCTGTCTGCC
Gfap Forward GCACGCAGTATGAGGCAATG 139
Reverse TAGTCGTTGGCTTCGTGCTT
Glast Forward GGCTAGCCTGCCTGCTTAC 165
Reverse TGTCTGGGAATCACCCACAG
Gs Forward CTTAACCCACCAACCTGCCTG 221
Reverse AGGTGGTCATGGTGGAAGGT
Kir2.1 Forward ACTCTCGTCGGACCCTCC 183
Reverse GCGACTTGTTGCTCAGGTTG
Lcn2 Forward GACCCGCAAAAGATGTATGCC 197
Reverse CTCACCACTCGGACGAGGTA
Mmp9 Forward CGACGTCTTCCAGTACCGA 81
Reverse TTCAACTCACTCCGGGAACTC
Mmp11 Forward CTGGGAGAAGACGGACCTCA 242
Reverse TCTTGGGGAAGAAGGCATGG
Mmp14 Forward GTGGTCTCGGACCATGTCTC 143
Reverse AGCCATATTGCTGTAGCCAGG
Ncan Forward GAGGTGCACTCAGATCCCTG 196
Reverse GGCAGACAAAGCCATTGACC
Pax2 Forward CCAGTTGTGACTGGTCGTGA 206
Reverse GGCATTAGTAAGGCGGGGTT
Pcan Forward TCCACAGATTTCAGTTTTGCAG 198
Reverse CCCCTCAGCTAGACCAATACG
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Table 2.3 (Continued)
S100β Forward GACCAGGAAGGGGTGAGACA 141
Reverse TGATGAGCTCCTTCAGTTCGG
Spp1 Forward AGCCAAACAACAAATGGGCA 199
Reverse AGATGGGTCAGGGTTTAGCC
Tlr4 Forward GTGAGACCAGAAAGCTGGGA 151
Reverse TGCCTAAATGCCTCAGGGGA
Timp2 Forward GGCGTTTTGCAATGCAGATG 72
Reverse TCGTTTCCAGAGTCCACTTCC
Txnip Forward TCAAGATGCCGAACCCTGTG 130
Reverse AGTGAGGGGCCAATATCCCT
Vim Forward GCAGGATTTCTCTGCCTCTTC 198
Reverse CTGCACTGAGTGTGTGCAATTT
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2.3 Results
2.3.1 Mu¨ller glia express bone morphogenetic protein type IA, IB and
activin receptor like kinase 2 receptors
BMPs bind preferentially to 3 type I receptors; receptor IA, IB, or activin receptor
like kinase 2 (ALK2). Double-label immunofluorescence was used to define if any of
the type I BMP receptors was expressed by Mu¨ller cells and/or retinal astrocytes.
Sections through adult murine retina were co-labeled with antibodies specific for GS,
which labels Mu¨ller glial cells and retinal astrocytes, and BMPR1A, BMPR1B, or
ALK2 (Figure 2.1). All three receptors showed similar labeling patterns in the retina
with Mu¨ller glial cell processes labeled in the outer nuclear layer (ONL), outer plex-
iform layer (OPL), and ganglion cell layer (GCL; Figure 2.1A–C). Photoreceptor
outer segments and ganglion cell bodies were also clearly labeled for all three recep-
tors. To confirm the label of Mu¨ller glial cells and their processes by antibodies to
type I receptors, enzymatically dissociated cells were co-labeled with antibodies to GS
and BMPR1A, BMPR1B, or ALK2 (Figure 2.1J–L). Immunolabeled Mu¨ller glia were
readily apparent in dissociated samples as they had retained their shape throughout
the processing. All three receptors appeared to co-label GS (+) cells, indicating that
the cells are responsive to BMPs in vivo.
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Fig. 2.1. Bone morphogenetic protein (BMP) type I receptors in the mature mouse
retina (Continued on next page).
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Fig. 2.1. Bone morphogenetic protein (BMP) type I receptors in
the mature mouse retina. A: Retinal sections of 4 week-old retina
double-labeled using antibodies that recognize Mu¨ller glial and reti-
nal astrocyte marker glutamine synthetase (GS) and BMP receptor
1A (BMPR1A). Thin plane confocal microscopy with y,z (strips to
right of panels), and x,z planes (strips at bottom of panels) are shown
in the last panels in the row. BMPR1A was localized to the Mu¨ller
glial processes in the outer nuclear layer (ONL) and in Mu¨ller glial cell
or retinal astrocyte processes in the ganglion cell layer (GCL, arrows
A–C). BMPR1A was also detectable in the photoreceptor outer seg-
ments, the inner plexiform layer (IPL), cell bodies within the ganglion
cell layer, and the nerve fiber layer (NFL). B: Retinal sections of 4
week-old retina double-labeled using antibodies that recognize GS and
BMPR1B. BMPR1B appeared to be localized to the outer segments
(OS), outer plexiform layer (OPL) and IPL and, Mu¨ller glial cell pro-
cesses as well as Mu¨ller glial/retinal astrocyte processes in the GCL
and NFL (arrows). C: Retinal sections of 4 week-old retina double-
labeled using antibodies that recognize GS and activin receptor like
kinase 2 (ALK2). The distribution of ALK2 receptors was similar to
that of BMPR1A, with the majority of signal being localized to the
end feet within the GCL and NFL. D: Mu¨ller glia isolated from P30
retinas were co-labeled for GS and BMPR1A, 1B and ALK2. The
isolated cells showed the distribution of receptors to be primarily in
the processes and the end feet of the Mu¨ller glia, as seen in the P30
tissues. n=3 different eyes for each label. Scale bar A=50 µm applies
to A–I. Scale bar J=30 µm applies to J–L.
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2.3.2 Bone morphogenetic protein 7 signaling components in the retinal
glia
The BMP signaling pathway members present in the Mu¨ller glial and retinal as-
trocytes were also investigated to determine which pathways might be activated in
the presence of BMPs. To investigate the canonical BMP pathway, sections were
co-labeled with antibodies against SOX2, which labels Mu¨ller glial cells, retinal as-
trocytes and cholinergic amacrine cells in the mature murine retina, and SMAD1.
SMAD1 was localized throughout cells of the INL and GCL, and was co-localized
with SOX2 (+) cells (Figure 2.2). To determine if the BMP-kinase pathway could
be activated in response to BMPs, sections through adult retina were co-labeled with
antibodies to GS and TAK1 (Figure 2.2). While TAK1 was prominently expressed in
the retina, most notably in a subpopulation of INL and GCL, little to no co-expression
could be detected in GS (+) cells (Figure 2.2). Last, potential involvement of the
FRAP-STAT pathway in Mu¨ller glial BMP signaling was investigated by co-labeling
sections with GS and FKBP12 (Figure 2.2). FKBP12 label was noted in the INL,
GCL, and inner plexiform layers (IPL). No apparent co-label was detected of FKBP12
and GS (Figure 2.2).
2.3.3 Bone morphogenetic protein 7 can trigger changes in retinal astro-
cytes and MIO-M1 Mu¨ller cells resembling mild reactive gliosis
The role of BMP7 in reactive gliosis was first tested by addition of the factor to an
in vitro system using isolated retinal astrocytes or a Mu¨ller glial cell line, MIO-M1
(Scheef et al. 2005; Sehgal et al. 2009; Limb, Salt, et al. 2002). Previously character-
ized, retinal astrocytes have been shown to express paired box 2 (PAX2), neurogenin
2 (NG2), and GFAP [115,116,118]. In order to use these cells, their ability to exhibit
changes associated with reactive gliosis had to first be determined. The cells were
briefly treated with vehicle or sodium peroxynitrite, a strong oxidizing agent that is
released by injured neurons and has been shown to trigger reactive gliosis (Pacher,
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Fig. 2.2. Bone morphogenetic protein (BMP) signaling components
in the Mu¨ller glia of adult mouse retina. A: Sections of 4 week-old
retina were subjected to double-label immunofluorescence with anti-
bodies specific for sex determining region Y box 2 (SOX2), which la-
bels Mu¨ller glia, retinal astrocytes, and cholinergic amacrine cells, and
intracellular members of the BMP pathway SMAD1 . SMAD1 (+)
cells were localized to the inner nuclear layer (INL) and ganglion cell
layer (GCL) of P30 retina. A subpopulation of SOX2 (+) Mu¨ller glia
(arrows) and retinal astrocyte cells (arrowheads) were also positive for
SMAD1. B: Sections of 4 week-old retina were subjected to double-
label immunofluorescence with antibodies for SOX2, and TGF-β ac-
tivated kinase 1 (TAK1). Cells positive for the protein TAK1 were
found to be localized in the INL and GCL. C: Sections of 4 week-old
retina were subjected to double-label immunofluorescence with anti-
bodies for SOX2, and FK506 rapamycin binding protein (FKBP12).
FKBP12, also part of the non-canonical BMP pathway, was found to
be localized in the INL along with sparse localization in the GCL.
Very little to no co-label was seen with glutamine synthetase (GS; +)
and TAK1 or FKBP12 (+) cells (B, C). Scale bar A=50 µm applies
to all panels.
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Beckman, and Liaudet 2007). Following treatment, levels of mRNAs known to be
regulated during reactive gliosis were examined 16 (not shown) and 32 h after treat-
ment using RT-qPCR (Figure 2.3).
In the analysis of the RT-qPCR levels throughout this study, two thresholds had to
be met in order for the change to be considered a convincing change; 1) the com-
parative change with controls had to be statistically significant, and 2) an average
increase in levels had to reach the level of 1.5 fold or above that of controls or, sim-
ilarly, a decrease had to reach a level 0.5-fold or below. No statistically significant
changes in expression were noted between vehicle and peroxynitrite 16 h following
treatment (not shown). In contrast, there were statistically significant increases that
reached the 1.5-fold threshold in the level of many mRNAs within the reactive gliosis
panel in peroxynitrite treated cells in comparison to vehicle-treated, including Pax2,
lipocalin2 (Lcn2 ), matrix metalloproteinase 9 (Mmp9 ), phosphacan (Pcan), S100β,
toll-like receptor 4 (Tlr4 ), tissue inhibitor of matrix metalloproteinase 2 (Timp2 ),
and glial fibrillary acidic protein (Gfap) (Figure 2.3A). There was also a statistically
significant decrease in the glutamate aspartate transporter (Glast) that also reached
the level of 0.5 and below threshold. Levels of protein were investigated by western
blotting for 3 proteins; namely GFAP, thioredoxin-interacting protein (TXNIP), and
PAX2 (Figure 2.3). While there was a modest increase in GFAP and PAX2 protein in
comparison to control vehicle-treated cells, there was no increase in levels of TXNIP
36 h post-treatment (Figure 2.3).
To test whether BMP7 treatment could also trigger signs of reactive gliosis in vitro,
retinal astrocytes were treated with either vehicle or BMP7 for 24 or 36 h. Following
24 h of vehicle or BMP7 treatment, retinal astrocytes treated with BMP7 showed a
statistically significant increase in transcript levels above the 1.5-fold threshold for
Ncan, Pcan, Asci1, Glast, Txnip, Pax2, and Gfap (Figure 2.3). There was also a
decrease in levels of Mmp14 in BMP-treated versus vehicle-treated retinal astrocytes
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Fig. 2.3. Bone morphogenetic protein 7 (BMP7) treatment of retinal astrocyte cells
increases markers of glial scar formation (Continued on next page).
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Fig. 2.3. Bone morphogenetic protein 7 (BMP7) treatment of retinal
astrocyte cells increases markers of glial scar formation. A: Expres-
sion patterns for a panel of markers associated with reactive gliosis
were compared in murine retinal astrocytes treated with sodium per-
oxynitrite or BMP7 for 24 or 36 h. Values represented are means
+/– SEM. Unpaired t test was performed between the control and
treated groups with ∗ denoting a p value<0.05 and ∗∗ denoting a p
value<0.005. Any change above or below 1.0 indicates a change rela-
tive to control values. Peroxynitrite-treated cells showed statistically
significant increases above 1.5-fold in mRNA levels of Pax2, Lcn2,
Mmp9, Pcan, S100β, Tlr4, Timp2 and Gfap. Decreases in mRNA
levels below 0.5-fold were noted for Glast in peroxynitrite-treated
cells. In comparison, 24 h of BMP treatment led to a modest increase
above the 1.5-fold level in Ncan, Pcan, Asic1, Glast, Txnip, Pax2,
and Gfap mRNA levels. By 36 h post BMP7-addition, Gfap levels
had returned to baseline and Asic1, Kir2.1, and Pax2 mRNA levels
were reduced in comparison to vehicle-treated cells. Levels of Mmp11,
Timp2, and Ncan were still increased in comparison to vehicle-treated
cells. B: Western blot analysis was performed for GFAP, TXNIP, and
PAX2, with β-TUBULIN used as a loading control. Densitometric
data shown are means +/– SEM of 3 trials. Unpaired t test was per-
formed between the control and treated groups with ∗ denoting a p
value<0.05 and ∗∗ denoting a p value<0.005. Densitometric analysis
of the blots showed a statistically significant increase in protein levels
of GFAP in the peroxynitrite and 24 h BMP7 treatments. Significant
increases in levels of PAX2 and TXNIP was observed in the perox-
ynitrite and 24 h BMP7 treatments, respectively. No statistically
significant change was observed in the 36 h BMP7 treatment.
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that met the 0.5 threshold and was a statistically significant change in comparison
to vehicle-treated cells (Figure 2.3A). Western blotting was used to assess the levels
of a subset of proteins in vehicle- and BMP-treated cells. A statistically significant
increase in protein levels of GFAP and TXNIP protein was noted for BMP7-treated
cells compared to vehicle-treated cells at 24 h post-treatment (Figure 2.3B).
However, there were no detectable differences in the levels of TXNIP or PAX2 at
24h (Figure 2.3). Cells treated with BMP7 for 36 h showed changes in levels of a
slightly different cohort of mRNAs; Mmp11, Timp2, Ncan, and Mmp9 were modestly
increased, while Asic1, Kir2.1 and Pax2 were decreased slightly (Figure 2.3B). By
western blotting there were small but statistically insignificant increases in GFAP,
TXNIP and PAX2 (Figure 2.3).
Similar to the retinal astrocyte cultures, treatment of the Mu¨ller glial cell line MIO-
M1 with peroxynitrite also led to increases in some of the markers in the reactive
gliosis panel (Figure 2.4). Western blots showed a modest increase in protein levels
of GFAP and S100β; however, no change was noted in PAX2 expression (Figure 2.4).
Treatment of MIO-M1 cells with BMP7 yielded similar, but slightly different changes
in mRNA levels following treatment for 24 or 36 h. At 24 h, Gfap and Pax2 mRNA
levels were increased in comparison to control vehicle-treated cells above the 1.5-fold
threshold, while there was a decrease in Txnip, Gal3, Lcn2 and Mmp9 levels below
the 0.5-fold threshold (Figure 2.4).
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Western blotting showed statistically significant changes in GFAP, S100β, and TXNIP
protein levels in comparison to controls; however increases in PAX2 were not statisti-
cally significant (Figure 2.4B). Treatment of cells with BMP7 for 36 h yielded increases
in Gfap and Tlr4 mRNA levels in comparison to control cultures and a decrease in se-
creted phosphoprotein 1 (Spp1 ; Figure 2.4B). By western blot, densitometric analysis
showed a statistically significant decrease in PAX2 levels and no significant changes
in GFAP, S100β, or TXNIP levels in comparison to vehicle-treated cells (Figure 2.4B).
To determine if treatment of cells with another BMP family member, BMP4, led to
similar changes in reactive gliosis markers, retinal astrocytes and MIO-M1 cells were
treated with BMP4 for 24 or 36 h, and changes in mRNA levels were assessed by
RT-qPCR. Overall there were fewer statistically significant changes in BMP4-treated
cells at or over the level of 1.5 fold increase or 0.5-fold decrease in comparison to
vehicle-treated cells in both retinal astrocytes and MIO-M1 cells (Figure 2.5). In
retinal astrocytes, Txnip and Gs were increased more than 1.5 fold over control and
were statistically significant. Only Mmp9 showed a decrease in comparison to control
at 24 h post-treatment. In comparison, at the 36 h time point only a decrease in
Mmp9 was statistically significant and reached the 0.5-fold level. In the MIO-M1
cells only Asic1 and Spp1 were up-regulated at least 1.5 fold over levels of control
mRNA at 24 h post-addition. Further, at the 36 h time point a statistically significant
increase at the 1.5-fold level in endothelin receptor type B (Ednrb) and Asic1 were
the only increases noted at 36 h post-addition of BMP4.
2.3.4 Intravitreal injection of bone morphogenetic protein 7 induces re-
active gliosis
To further explore the role of BMP7 in reactive gliosis, wild type adult mouse eyes
underwent intravitreal injections of vehicle or BMP7. To determine the BMP signal-
ing cascade in BMP7 mediated gliosis, the vehicle- and BMP7-injected retinas were
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Fig. 2. 4. Bone morphogenetic protein 7 (BMP7) treatment of MIO-M1 Mu¨ller glial
cell line increases glial fibrillary acidic protein (GFAP) expression (Continued on next
page).
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Fig. 2.4. Bone morphogenetic protein 7 (BMP7) treatment of MIO-
M1 Mu¨ller glial cell line increases glial fibrillary acidic protein (GFAP)
expression. A: Expression patterns for a panel of markers associated
with reactive gliosis were compared in human MIO-M1 Mu¨ller glial
cells treated with sodium peroxynitrite, or BMP7 for 24 or 36 h. For
each experimental treatment, cells were treated with vehicle, sodium
peroxynitrite, or BMP7 and real-time quantitative PCR (RT-qPCR)
was undertaken. Values represented are means +/–SEM. Unpaired
t test was performed between the control and treated groups with
* denoting a p value<0.05 and ∗∗ denoting a p value<0.005. Any
change above or below 1.0 indicates a change relative to control val-
ues. BMP7-treated MIO-M1 cells showed a statistically significant in-
crease above the 1.5-fold level in Pax2, Asic1, Lcn2, Kir2.1, Gfap, and
Pcan in comparison to vehicle-treated cells. Twenty-four hours fol-
lowing BMP7 addition, the MIO-M1 cells only showed a statistically
significant increase above the 1.5-fold level in Gfap and Pax2, and a
decrease in Txnip, Gal3, Lcn2, and Mmp9. At the 36 h time point
Gfap, and Tlr4 levels of mRNA were increased above the 1.5-fold
level in comparison to vehicle-treated cells and Spp1 was decreased.
B: western blot analysis was performed for GFAP, S100β, TXNIP,
and PAX2, with β-TUBULIN used as a loading control. Densito-
metric data shown are means+/–SEM of 3 trials.Unpaired t test was
performed between the control and treated groups with ∗ denoting a p
value<0.05 and ∗∗ denoting a p value<0.005. Densitometric analysis
of the blots showed a statistically significant increase in protein levels
of GFAP and TXNIP in the peroxynitrite treatment. A significant
increase in levels of GFAP, S100β, and TXNIP was observed in the
24 h BMP7 treatment, while a significant decrease was observed in
PAX2 levels in the 36 h bmp7 treatment.
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Fig. 2.5. Retinal astrocytes and MIO-M1 cells show an attenuated
response to bone morphogenetic protein 4 (BMP4). Retinal astro-
cytes (RAC) and MIO-M1 cells were treated with BMP4 and mRNA
isolates from samples treated for 24 h or 36 h were subjected to real-
time quantitative PCR (RT-qPCR) using the reactive gliosis panel
established in previous experiments. Values represented are means
+/–SEM. Unpaired t test was performed between the control and
treated groups with ∗ denoting a p value<0.05 and ∗∗ denoting a p
value<0.005. At 24 h, retinal astrocytes treated with BMP4 showed
statistically significant increase above the 1.5-fold level in Txnip and
GS in comparison to controls, as well as a decrease in Mmp9. By 36
h, statistically significant decreases in GS and Mmp9 in comparison
to vehicle were noted. Similarly, MIO-M1 cells treated showed small
changes in Asic1, Glast and Spp1, following 24 h of BMP4 treatment.
At 36 h, increases above 1.5-fold in Ednrb and Asic1 in comparison
to controls were noted.
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colabeled with SOX2 and phospho-SMAD 1/5/8 (Figure 2.6) or phospho-TAK1 (Fig-
ure 2.7). While the vehicle-injected retina showed little or no phospho-SMAD and
SOX2 co-label, the BMP7 injected retinas showed an increased colabel for phospho-
SMAD 1/5/8 and the Mu¨ller glial marker SOX2 (Figure 2.6). Co-label was also
performed for SOX2 and phospho-TAK1 to determine activation of the BMP-MAPK
non-canonical signaling cascade. The vehicle-injected retina showed phospho-TAK1
label primarily in the ganglion cell layer, while the BMP7-injected retina showed an
increase in the phospho-TAK1 label in the inner nuclear layer and an increase in
co-label with SOX2 (Figure 2.7).
Further, retinas at 3 and 7 days after injection were examined using RT-qPCR, im-
munofluorescence, and Western blot analysis. Three days following injection, the
only statistically significant changes that reached threshold was a decrease in Pax2
and Gal3 mRNA levels (Figure 2.8A). At the 7 day time point, however, statisti-
cally significant increases in mRNA levels above threshold were observed for Txnip,
Glast, Mmp9, Lcn2, Gs, Kir2.1, and Mmp14 (Figure 2.8 A). There were also several
decreases noted at 7days after injection; Tlr4, Pax2, and Egfr. Immunohistochem-
istry on sections through injected retinas at 3 days post-injection revealed no readily
apparent changes in GFAP, S100β or NCAN in BMP7-injected retinas as compared
to vehicle-injected (Figure 2.8B). In contrast, there was a marked increase in GFAP,
S100β and NCAN in BMP7-injected retinas when compared with their control coun-
terparts (Figure 2.8B). By western blot, there were small but significant increases in
S100β and TXNIP at 3 days post-injection in BMP7-injected retinas and, while there
were increases in GFAP, S100β and TXNIP at 7 days post-injection in BMP-injected
retina, none of the changes were statistically significant (Figure 2.8C).
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Fig. 2.6. Canonical bone morphogenetic protein (BMP) signaling is
activated in the Mu¨ller glia in BMP7 injected murine eyes. Sections
of retina from adult mouse eyes injected with vehicle or BMP7 and
harvested 3 or 7 days after injections were double-labeled with anti-
bodies against phospho-SMAD1/5/8 (green) and the nuclear marker
sex determining region Y box 2 (SOX2; red) which labels Mu¨ller glia,
retinal astrocytes and cholinergic amacrine cells. While the vehicle-
injected control showed phospho-SMAD 1/5/8 labeled cells primarily
localized in the ganglion cell layer (GCL), with little or no co-label
with the SOX2 (+) cells, in the D3 and D7 BMP7-injected retinas,
phospho-SMAD1/5/8 label was also detectable in the inner nuclear
layer (arrows INL). A sub population of the cells in the INL which
were positive for phospho-SMAD1/5/8 were also SOX2 positive. n=3
different retinas for each immunolabel. Scale Bar A=50 µm applies
to all panels.
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Fig. 2.7. Non-canonical bone morphogenetic protein (BMP) signaling
mediated via Transforming Growth Factor-β activated kinase (TAK)
is upregulated in the Mu¨ller glia in BMP7 injected murine eyes. Reti-
nal sections from mouse eyes processed 3 and 7 days following injection
with either vehicle or BMP7 were co-labeled with antibodies against
phospho-TAK1 (green) and Mu¨ller glial marker sex determining re-
gion Y box 2 (SOX2; red) . The vehicle injected control retinas for 3
and 7 days (D3 and D7 respectively) showed phospho-TAK1 label pri-
marily cells in the ganglion cell layer (GCL), with no phospho-TAK1
labeling in the iner nuclear layer (INL) or outer nuclear layer (ONL).
SOX2 (+) reinal astrocytes were observed in the GCL, however very
little co-expression was observed with phospho-TAK1 in the vehicle
injected retinas. The BMP7-injected retinas did show an increase in
phospho-TAK1 expression in the INL, showing a comparatively higher
expression in the BMP7-injected retina at 3 days than at 7 days. A
subpopulation of the SOX2 (+) in the GCL and INL were co-labeled
with phospho-TAK1 in the BMP7-injected retinas (arrows). n=3 dif-
ferent retinas for each immunolabel. Scale Bar A=50 µm applies to
all panels.
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Fig. 2.8. Intravitreal injection of bone morphogenetic protein 7 (BMP7) into murine
eyes leads to reactive gliosis (Continued on next page).
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Fig. 2.8. Intravitreal injection of bone morphogenetic protein 7
(BMP7) into murine eyes leads to reactive gliosis. A: RNA from adult
eyes injected with vehicle or BMP7 was isolated 3 and 7 days following
injections and real time quantitative PCR (RT-qPCR) was performed
using the reactive gliosis panel described in previous figures. Values
represented are means+/ −SEM. At 3 days following injection, there
was a significant decrease in Pax2 and Gal3. In contrast, by 7 days
following injection there were significant increases in Txnip, Glast,
GS, Mmp9, Lcn2, Kir2.1, and Mmp14 and decreases in Tlr4, Pax2,
and Egfr. B: Immunolabel of retinas from 3 day and 7 day vehicle and
BMP7-injected eyes for a subset of the gliosis markers. To confirm
some of the changes seen at the mRNA level, eyes injected with vehicle
or BMP7 were fixed 3 or 7 days after injection and immunolabeled for
GFAP, S100β, or NEUROCAN (NCAN). At 3 days following injec-
tion, GFAP, S100β and NCAN immunolabel looks similar in vehicle-
and BMP7-injected eyes. In contrast, by 7 days, sections immuno-
labeled for GFAP, S100β, and NCAN showed an increase in labeling
in BMP7-injected eyes in comparison to vehicle-injected. C: western
blot analysis was performed for GFAP, TXNIP, S100β, and PAX2,
with β-TUBULIN used as a loading control. Densitometric analysis
of the blots showed a statistical increase in protein levels of S100β at
the 3 day stage. While there did appear to be an increase in GFAP,
S100β, and TXNIP at 7 days following injection in the BMP7-treated
retinas as compared to vehicle-injected, none of the changes in protein
levels was statistically significant. Scale bar C=50 µm applies to C–P.
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2.4 Discussion
Our findings indicate that the BMP7 pathway plays a role in triggering and/or main-
taining reactive gliosis in the retina. The glial cells of the retina express the BMP
receptors (BMPR1A, BMPR1B and ALK2). While the downstream components for
the canonical and non-canonical signaling pathways are present in the retina, only the
SMADs appeared to be present in the retinal glia prior to BMP7 injection. Following
injection, both activated SMADs and TAK1 were present, indicating that TAK1 had
been upregulated following injection. Treatment of retinal astrocyte cells and Mu¨ller
glial cells in vitro with BMP7 regulated various reactive gliosis markers. The pro-
file of gliosis markers regulated due to exposure to BMP7 was similar, although not
identical, to that observed due to exposure to peroxynitrite. Injection of BMP7 into
mouse retina also triggered a reactive gliosis response. Incubation of cells with BMP4,
however, showed no significant increase or decrease in the levels of the gliosis markers.
2.4.1 Regulation of glutamine synthetase during reactive gliosis
Reactive gliosis is a common and a complex response observed following neural in-
jury [119]. One response typical of Mu¨ller cells undergoing gliosis is a change in
levels of glutamine synthesis, the enzyme critical for glutamate-glutamine cycling in
the nervous system. Under normal circumstances within the retina, GS prevents the
excitotoxic effects of glutamate and is necessary for ammonium detoxification [21].
In the retina, GS is widely expressed in the astrocytes and Mu¨ller glial cells [120].
Levels of GS are exquisitely regulated by injury in an injury- or disease-state manner.
For instance, expression of GS is downregulated in diseases states in which photore-
ceptors (the major source of glutamate in the retina) degenerate [121,122]. However,
in disease states where the presence of GS is necessary to detoxify the retina when
high levels of ammonia, glutamate, or glutamate agonists are present (such as hep-
atic retinopathy or following kainic acid injection), expression levels of the enzyme
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increase [123,124]. Finally, levels of GS can remain stable in some injury and diseases
states including diabetic retinopathy and following nerve crush [125,126]. In the stud-
ies presented here, GS levels increased following addition of BMP7 in vitro and in
vivo, suggesting that the BMP7 addition mimics situations where there is an increase
in glutamate or NH4+ concentrations in the retina. Further studies will be necessary
to determine if differential regulation of BMP7 occurs in a disease-dependent manner.
2.4.2 Bone morphogenetic protein 7 triggers reactive gliosis via the SMAD
and the transforming growth factor-β activated kinase pathway
Reactive gliosis encompasses a wide range of responses ranging from hypertrophy to
regulation of transporter channels and enzymes, as well as cell migration, proliferation
and de-differentiation [43]. The triggers for these different molecular and functional
responses vary with the injury or disease state. Many growth factors have been impli-
cated in regulating one or more of the changes associated with gliosis. For instance,
EGF has been associated with Mu¨ller glial proliferation, FGF2 with the scarring re-
sponse, and CNTF with GFAP upregulation [104,108]. Further, inflammation is also
a commonly observed response during gliosis. Factors such as TNF-α and CNTF
have been known to play a role in inflammatory response of reactive gliosis, while
TNF-α and some of the interleukins are also known to induce proliferative reactive
gliosis [68, 127,128].
BMPs have also been associated with various changes that occur during reactive
gliosis; however many of the studies to date have focused on the role of the BMPs
following injury to the spinal cord [77, 81, 129]. Initial studies indicated that BMP
signaling increased at the site of spinal cord lesions and treatment of astrocytes in
vitro with BMPs 4 or 7 increased expression of chondroitin sulfate proteoglycans typ-
ically associated with glial scars [77]. Further, inhibition of BMPs following spinal
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cord injury leads to a decrease in chondroitin sulfate proteoglycans and an increase in
the ability of axons to regenerate over time [77, 129]. Similarly, knockout studies for
two of the Type 1 BMP receptors have shown that BMPR1A is critical in the hyper-
trophy response that occurs early in reactive gliosis and BMPR1B is critical for some
aspects of the scarring response. Little is known about the role of BMPs in injury or
disease within the retina and/or optic nerve. Detailed descriptions of the expression
patterns of the BMPs, BMP receptors, and several BMP binding proteins have been
described in developing and adult optic nerve, optic nerve head and trabecular mesh-
work [111, 130, 131]. An increase in BMP signaling within the trabecular meshwork
has been implicated in blocking TGF -β driven changes in gene expression [132–134].
Finally, BMP stimulation downstream of EGF signaling has recently been implicated
in Mu¨ller glial cell proliferation [135].
In the studies detailed here, we showed that the Mu¨ller glial cells express BMPR1A,
BMPR1B, and ALK2 receptors. While it is probable that astrocytes are also ex-
pressing the receptors, due to the intensity of the label in the ganglion cell and
inner limiting membrane area we were unable to ascertain this for certain. BMP7
preferentially binds ALK2 receptor and transduces signal via SMAD 1/5/8 [73]. To
determine BMP signaling in the retinas, we first analyzed expression and glial local-
ization of the canonical and non-canonical BMP signaling components: SMAD, TAK
and FRAP. While co-label showed SMAD and TAK to be localized with Mu¨ller glia,
with SMAD comparatively to be more than TAK, FRAP showed no localization (Fig-
ure 2.2). Analysis of the activated phosphorylated forms of SMAD (phospho-SMAD)
and TAK (phospho-TAK) revealed that there is an activation of both in the BMP7-
injected retinas (Figure 2.6 and Figure 2.7).
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Apart from the glial cells, several other cells also showed positive label for both
phospho-SMAD and phospho-TAK. This upregulated BMP signaling in both macroglial
and other cells of the retina suggests that BMP7 can regulate gliosis either by directly
acting on the retinal glia or indirectly by regulating other retinal cells.
In comparison to BMP7, treatments with BMP4 did not appear to induce gliosis in
retinal astrocytes or Mu¨ller cells in vitro. While BMP4 has been shown to have a
neuroprotective effect when injected prior to a toxic insult, BMP7 was not shown
to have the same protective effect [69]. The differential response of retinal neurons
and macroglia to BMP4 and 7 is indicative of the involvement of different signaling
pathways, but further study is necessary in order to elucidate the mechanism of this
differential response.
2.4.3 Differences in response patterns
Apart from growth factors, various molecular factors such as adenosine tri-phosphate
(ATP), nitric oxide (NO) etc. can also trigger reactive gliosis [43]. Although role
of specific factors have been implicated in certain aspects of gliosis such as GFAP,
vimentin and neurofilament expression [69, 136], there does not seem to be a clear
correlation between the various gliosis markers and its regulators. GFAP is used as
the standard indicative for gliosis. However, it and other markers such as GS, MMPs
and others have been shown to be regulated differentially depending on the stress
they are subjected to [121, 126, 137, 138]. In this study, RT-qPCR analysis of RNA
from BMP7-injected retinal tissue compared to the RNA prepared from treated reti-
nal astrocytes and Mu¨ller glial cells showed a greater deviation from their respective
control treatments (Figure 2.3, Figure 2.4, and Figure 2.8). This could be attributed
to the fact that the cells in vitro represented a pure population of cells, while the
retinal tissue represented a mixed population of macroglia, microglia, neurons, as
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well as components of the vasculature. We also observed differences in the profile
of regulated genes between the sodium peroxynitrite and BMP7 treated cells. This
observation is consistent with the idea that various factors are responsible for driving
specific aspects of the gliosis response [3, 69,102].
In addition to differential expression between peroxynitrite and BMP7 treatments
in vitro, as well as in vivo versus in vitro responses, we also noted that there were
substantial differences between the regulation of various markers at the mRNA and
protein level. The asymmetry has also been noted by other investigators who have
compared mRNA and protein levels, indicating that there may be multiple levels of
regulation involved in gliosis [76, 139–142]. Although mRNA levels showed increased
regulation both in vivo and in vitro, a similar change was not detected at the protein
level. mRNA translation and protein levels are regulated in the cell by a number
of systems: regulation of mRNA localization and translational repression mediated
by RNA binding proteins, regulation via micro RNAs, ubiquitin proteasome system
as well as changes in protein stability [143, 144]. Here we do not observe a linear
correlation between the mRNA and protein levels in the gliosis models analyzed.
We, thus, hypothesize that protein is regulated at the mRNA translation level, me-
diated either by RNA binding proteins or by micro RNAs. Furthermore, protein
stability may also be regulated in BMP7 mediated gliosis leading to differences in
mRNA and protein levels. mRNA binding protein such as cytoplasmic polyadenyla-
tion element binding protein (CPEB) has been previously shown to upregulated in
the gliosis [145]. One of the downstream targets of the TAK mediated BMP cascade is
the p38-MAPK [73,146]. p38-MAPK can regulate the phosphorylation, and thereby,
activation of CPEB [145]. Micro RNAs (miRNAs) are small 22-25 nucleotide long
non coding RNA which play an important role in cell fate and development. miRNAs
have been found which are specific to the nervous system and also to the retina, and
BMPs have also been shown to regulate miRNA levels [147–150]. Further, regula-
tion of miRNAs have also been observed in astrocytes following injury in the spinal
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cord [151]. The miRNAs bind to their target RNA and can either direct it to degra-
dation or can repress translation. Competing endogenous RNA (ceRNA) interaction
mediated by miRNA which can target more than mRNA has been previously reported
in diabetic retinopathy in RPE cells [152]. Similar interactions may also be prevalent
in the glial cells leading to translational regulation.
In this study, we observe a more severe response in gliosis in vivo as compared to
in vitro. Immunohistochemistry for BMP receptors in mouse retina showed a large
population of neuronal cells other than Mu¨ller glia and retinal astrocytes to also ex-
press them. Thus, binding of BMP7 to receptors in these cells and also to Mu¨ller
glia, could amplify the gliosis signal leading to a comparatively severe response in the
mouse retina.
2.4.4 Extracellular matrix and reactive gliosis
One of the responses seen during reactive gliosis is extracellular matrix modifica-
tions. These changes in the matrix are primarily due to the regulation of MMPs,
which remove extracellular matrix molecules, and the regeneration-inhibiting chon-
droitin sulfate, ultimately leading to the formation of a glial scar [43, 153]. The
formation of the scar serves to protect the injured site while also preventing axonal
regrowth [110].We observe here an increase in RNA levels of extracellular matrix
molecules such as Ncan, Pcan and Mmps, both in vivo and in vitro (Figure 2.3,
Figure 2.4 and Figure 2.8). Furthermore, immunohistochemistry of the BMP7 in-
jected mouse retina also showed an increase in localization of NCAN in the inner
nuclear layers of the retina (Figure 2.8). Other members of the TGF-β family have
been previously shown to increase proteoglycan production in reactive glial cells [103].
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We observe here an increase in NCAN at the 7 day stage when compared to the
earlier 3 day time point, a result similar to a previous study [103]. Further study is
necessary to determine if the effects of BMPs on the extracellular matrix production
are direct or indirect.
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3. MICROGLIA ACTIVATION IS ESSENTIAL FOR
BMP7-MEDIATED RETINAL REACTIVE GLIOSIS
3.1 Introduction
The mammalian retina consists of at least two distinct glial populations. The macroglia,
which includes Mu¨ller glia and retinal astrocytes, and the microglia. The Mu¨ller glia
are the primary glial cells found in the retina, having their nucleus in the inner nu-
clear layer (INL) with processes extending from the inner limiting membrane at the
vitreal border to the outer limiting membrane at the base of photoreceptor inner
segments [11]. Retinal astrocytes migrate into the retina from the optic nerve and
reside in the nerve fiber layer [154]. The microglia are the resident macrophages found
scattered through all the retinal layers [33]. The retina of some species also contain
oligodendrocytes and another glial-like cell type, known as the non-astrocytic inner
retinal glia-like (NIRG) cells, that reside in the INL of the chick retina [79,155].
Mu¨ller glial cells and retinal astrocytes are essential for maintaining retinal homeosta-
sis. Any injury or disease leading to retinal damage or disruption of the homeostasis
triggers the glial cells to become active, a response termed reactive gliosis. Reactive
gliosis has been observed in all retinal disease and injury models including glau-
coma, age related macular degeneration, and diabetic retinopathy [42, 46, 78, 156].
Reactive gliosis is characterized by hypertrophy, altered function brought about by
changes in expression of proteins such as glutamine synthetase (GS), S100β, extra-
cellular matrix proteins, chondroitin sulphate proteoglycans (CSPG), matrix metal-
loproteinases (MMP), and an increase in growth factors such as ciliary neurotrophic
factor (CNTF), leukemia inhibitory factor (LIF), and vascular endothelial growth
factor (VEGF) [41,157]. Multiple factors can trigger gliosis, including the bone mor-
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phogenetic proteins (BMPs) [65, 81, 158]. Recent evidence from the Belecky-Adams
laboratory showed that BMP7 triggered gliosis in both the Mu¨ller glia and astrocytes
of the mouse retina; however, the mechanism by which BMP7 triggers gliosis is un-
known [157].
The BMPs are growth factors that belong to the transforming growth factor beta
(TGF-β) superfamily. BMP signaling is initiated following the binding of the ligand
to serine threonine kinase receptors. This leads to the activation of the receptors
and the subsequent phosphorylation and activation of downstream signaling compo-
nents. In the canonical pathway, the BMP signals by phosphorylation and activation
of downstream receptor SMADs (RSMADs). The RSMADs form a dimer with the
co-SMAD (SMAD4) and are shuttled to the nucleus to regulate transcription. BMP
can also mediate the activation of a non-canonical pathway referred to as the BMP
mitogen -activated protein kinase pathway (BMP-MAPK). In the BMP-MAPK path-
way, the receptors recruit the X-linked inhibitor of apoptosis (XIAP) to a complex
containing TAB1 and TAK1, thereby activating TAK1. TAK1 then activates down-
stream kinases, eventually activating NF-κB, p38 and JNK MAPKs [73, 75]. In the
CNS, BMP regulation has been observed in various diseases and injury models, such
as spinal cord injuries, axonal damage and ischemia [77,158,159]. In the retina, upreg-
ulation of BMPs and their signaling components are observed in the photo-damaged
retina injury model and in diabetic retinopathy [133,160,161].
Microglia are the innate immune cells of the retina. In their resting state, the mi-
croglia act as sentinels, extending their processes throughout the retina. In the mouse
retina, the microglia are initially found in the ganglion cell layer, entering the retina
from the ciliary marginal zone and vitreous. By post natal day 7, the microglia
spread to the rest of retinal layers, finally resting in the plexiform layers [162]. Upon
receiving signals from injured or dying cells, the microglial cells become activated:
they retract their processes, undergo an increase in cellular area, become amoeboid in
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shape, and migrate to the area of injury or disease to phagocytize cellular debris and
metabolic products [31, 163]. Stimuli such as neuronal loss or damage, inflammation
and nerve degeneration, activate the microglia into a motile effector cell with altered
morphological characteristics [164,165].
Microglial activation has been observed in all retinal diseases, including diabetic
retinopathy, age related macular degeneration, glaucoma and models of retinal patholo-
gies. In addition to the morphological changes following activation, microglia also in-
duce a change in production of various cytokines such as interleukin 1 beta (IL-1β), IL-
6 and interferon gamma (IFN-γ), chemokines such as regulated on activation, normal
T cell expressed and secreted (RANTES), monocyte chemotactic protein 1 (MCP1);
growth factors such as colony stimulating factor (CSF) and VEGF, and various scav-
enger receptors and antigen presenting molecules such as the scavenger receptor A
(SR-A) and major histocompatibility complex (MHC), respectively / [33, 54]. Fur-
thermore, research has revealed that activated microglia can be further classified into
the following phenotypes: the M1 or pro-inflammatory phenotype, and the M2 or the
anti-inflammatory phenotype [55, 166]. Polarization to the M1 phenotype, following
exposure to factors such as lipopolysaccharide (LPS) and IFN-γ, the microglia upreg-
ulate pro-inflammatory factors such as IL-1β, tumor necrosis factor alpha (TNF-α),
inducible nitric oxide synthase (iNOS), SRs and MHC-II [167, 168]. The M2 pheno-
type plays a role in the resolution of the inflammation and tissue remodeling. This
phenotype is induced by factors such as IL-4 and IL-10 or through the maturation of
the M1 cells. This phenotype was characterized by an upregulation of markers such
as arginase-1 (Arg-1) and mannose receptor (Mr), cytokines such as IL-10, IL-13 and
growth factors such as TGF-β and VEGF [167,169].
Signals from neurons and macroglia, such as fractalkine, neurotransmitters and neu-
rotrophins help keep the glial population in the quiescent state [42, 170]. Activation
of the glial cells has been found to be mediated by similar stimuli in vitro and in
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retinal disease models in vivo [42, 164, 171, 172]. Cytokines and other inflammatory
markers such as TNF-α, iNOS, CNTF and LIF are not only regulated during gliosis,
but are also factors known to act on the glial cells and regulate gliosis [68, 160, 173].
Activated microglia are known to regulate Mu¨ller cell activity directly, regulating cell
morphology, proliferation and gene expression [59,165]. Activated microglia can also
regulate the generation of Mu¨ller glia-derived progenitors [174]. Here we provide evi-
dence that supports the hypothesis that BMP7 indirectly triggers gliosis by activating
the pro-inflammatory state of retinal microglia.
3.2 Methods
3.2.1 Cell culture
Mouse retinal astrocytes were isolated in the Sheibani lab and maintained as previ-
ously described in [116, 157]. Microglial cells were isolated from retinas of newborn
(P0-P4) immortomouse back crossed into C57BL/6J as described in [175] with some
modifications. Briefly, the retinas were placed in a solution of Trypsin/EDTA (5 ml;
0.25% trypsin and 1 mM EDTA; ThermoFisher Scientific) and incubated at 37◦C for
5 min. Following incubation, the samples were triturated by pipette, and 5 ml of
DMEM with 10% FBS was added to stop trypsin activity. The digested tissue was
centrifuged for 5 min at 400xg at room temperature, the supernatant was carefully
aspirated, the pellet re-suspended in the microglia medium [a 1:1 mixture of DMEM:
F12 (ThermoFisher Scientific) containing 10% FBS, and 44 U/ml of interferon-γ
(R&D Systems, Minneapolis, MN)], plated on a single well of a 6-well plate, and
incubated in a tissue culture incubator at 33◦C and 5% CO2. The cells were allowed
to grow for 1-2 weeks and fed every 3-4 days until nearly confluent. The medium was
then removed from the plate and rinsed with PBS containing 0.04% EDTA. The plate
was then incubated with 2 ml of PBS containing 0.04% EDTA and placed on a multi-
purpose rotator at 100 rpm at room temperature for 20-30 min. The supernatant was
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collected in a 15 ml tube containing 3 ml of DMEM with 10% FBS and centrifuged
at 400xg for 5 min. The detached cells were then re-plated in the microglia medium,
allowed to reach confluence, and expanded into 60 mm dishes. The purity of the
microglial cultures was inspected by immunocytochemical staining and flowcytomet-
ric analysis for F4/80 (eBiosciences; San Diego, CA) and keratin sulfate (Seikagaku
Corporation; Jersey City, NJ). The purity of culture was nearly 95% using FACS
and immunostaining analysis. Astrocytes and microglia were grown in tissue culture
dishes (BD Falcon) in an incubator with 5% CO2 at 33
◦C, and passaged every 5-7
days using trypsin-EDTA and the medium changed every 3-4 days. Cells were treated
with 1µl/ml vehicle (4mM HCL with 0.1%BSA), 100 ng/ml of mouse bone morpho-
genetic protein 7 (BMP7; R&D systems), 300 ng/ml mouse interferon-gamma (IFN-γ;
R&D systems) or 100 ng/ml LPS (Sigma). Medium from microglial cells incubated
with BMP7 or vehicle (conditioned medium) for 24 hour (h) was used to treat retinal
astrocytes. The conditioned medium was added to the retinal astrocytes medium at
25% concentration in the presence of DMSO or 2.5 µM ALK2/ALK3/ALK6 inhibitor
LDN193189 (Cuny et al. 2008). The retinal astrocytes were allowed to grow for 24
h, after which cells were harvested for RNA isolation and RT-qPCR analysis.
3.2.2 Experimental groups
Experiments were carried out in 4 - 8 weeks old male C57BL/6J. All procedures
were in accordance with the guidelines set by the Institutional Animal Care and Use
Committee (IACUC) at the school of science IUPUI (protocol number SC230R). For
BMP7 injection studies, n=8 mice were used with the left eye injected with the vehi-
cle and the right eye injected with BMP7. For the PLX studies, two groups of mice
were considered, the age matched control chow group (n=12) and the PLX group
(n=12), kept on PLX chow diet. For the PLX BMP7 injection studies, two groups
of mice were considered: the age matched control group (n=12) and the PLX group
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(n=12), kept on the PLX diet. Both the groups were injected with the vehicle con-
trol in the left eye and BMP7 in the right eye. P30 VE-YFP mice (n=3), which
express YFP in endothelial cells, generated by crossing a line of mice containing an
enhanced yellow fluorescent protein (YFP) with a floxed stop sequence upstream of
the YFP (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J; strain number 006148 Jack-
son laboratory) [176] with the VE-cadherin-cre line (B6.FVB-Tg(Cdh5-cre)7Mlia/J;
stock number 006137 Jackson laboratory) (Alva et al. 2006), were used for immunoflu-
orescence experiments determining PU.1 co-localization in the retina.
3.2.3 Intraocular Injections
Postnatal day 30 (P30) C57BL/6J mice were anaesthetized with ketamine and xy-
lazine cocktail. Mice were injected intravitreally with 1 µl of vehicle (4mM HCL with
0.1%BSA) or 1 µl BMP7 (20 ng/µl) as previously stated in [157]. Intraocular injec-
tions were performed using a manual microsyringe (World precision instruments) and
pulled glass micropipettes.
3.2.4 Microglia Ablation
C57BL/6J mice were kept on chow feed containing 1200 ppm PLX5622 (PLX; Plexxikon
Inc.) for up to 21 days, starting at P30. Eyes were harvested at 7, 14 and 21 days
following start of the PLX diet for assessment of loss of microglia. The control mice
were kept on the control chow supplied by Plexxikon Inc. To determine if loss of mi-
croglial cells affected BMP7-mediated gliosis, mice were maintained on PLX chow for
the entirety of the experiment. In some animals, eyes were injected with 1µl vehicle
(4mM HCL with 0.1%BSA) or 1µl (20ng/µl) BMP7 14 days following treatment with
PLX, and eyes were harvested and processed 3 and 7 days post-injection.
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3.2.5 Tissue Processing
Eyes from euthanized C57BL/6J mice were enucleated, washed in PBS, and either
fixed in 4% paraformaldehyde (PFA) for immunofluorescence (IF) or dissected to
isolate retina for preparation of RNA and/or protein. For IF analysis, enucleated
eyes were washed and fixed in 4% PFA, incubated in ascending series of sucrose and
frozen in a sucrose OCT solution as previously described [157] Thick sections (12 µm)
were cut using Leica CM3050S cryostat onto Superfrost Plus slides (ThermoScientific)
and stored at -80◦C until use. Retinas from enucleated eyes were isolated as previously
described [157]. Isolated retinas were immediately processed for RNA isolation using
RNeasy kit (Qiagen).
3.2.6 RT-qPCR
Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) was per-
formed to detect changes in markers associated with gliosis and inflammation as
previously described [157]. The primers for RT-qPCR analysis are listed in Table
2.2. Included in this table is the accession number of each gene, the sequence of each
primer, product length, and calculated efficiency of each primer. Primers used for
assessing changes in inflammation are listed in Table 3.1. RT-qPCR was performed
using SYBR green master mix (Roche) with the reactions carried out in the LighCy-
cler480 system (Roche). The change in RNA levels was measured using the 2 −δδCt
method, where Ct is the crossing threshold / crossing point (Cp) value. Relative
RNA levels were calculated using the geometric means from the Ct value derived
from three housekeeping genes: β- 2 Microglobulin (β2m), succinate dehydrogenase
complex subunit A (Sdha) and signal recognition particle 14kDa (Srp14). A no tem-
plate control was also tested for each marker.
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Table 3.1.
List of RT-qPCR primers
Gene Primer Sequence Length (bp)
Ccl5 Forward TGCCCACGTCAAGGAGTATTT 111
Reverse ACCCACTTCTTCTCTGGGTTG
Cd45 Forward TGACCATGGGTTTGTGGCTC 134
Reverse TTGAGGCAGAAGAAGGGCAT
Cd68 Forward AAGGGGGCTCTTGGGAACTA 139
Reverse AAGCCCTCTTTAAGCCCCAC
Csf1 Forward ACCAAGAACTGCAACAACAGC 91
Reverse GGGTGGCTTTAGGGTACAGG
Iba1 Forward ACGAACCCTCTGATGTGGTC 118
Reverse TGAGGAGGACTGGCTGACTT
Il-1β Forward TGTCTGAAGCAGCTATGGCAA 141
Reverse GACAGCCCAGGTCAAAGGTT
Il-6 Forward ACTTCACAAGTCGGAGGCTT 111
Reverse TGCAAGTGCATCATCGTTGT
Ifn-α Forward CAAGCCATCCCTGTCCTGAG 131
Reverse TCATTGAGCTGCTGGTGGAG
Ifn-γ Forward CAACAGCAAGGCGAAAAAGGA 90
Reverse AGCTCATTGAATGCTTGGCG
Irf8 Forward CGGATATGCCGCCTATGACA 73
Reverse CTTGCCCCCGTAGTAGAAGC
Gm-csf Forward AGTCGTCTCTAACGAGTTCTCC 178
Reverse AACTTGTGTTTCACAGTCCGTT
Sdha Forward GGACAGGCCACTCACTCTTAC 130
Reverse CACAGTGCAATGACACCACG
Srp14 Forward CCTCGAGCCCGCAGAAAA 134
Reverse CGTCCATGTTGGCTCTCAGT
Thbs1 Forward GCCACAGTTCCTGATGGTGA 149
Reverse TTGAGGCTGTCACAGGAACG
Thbs2 Forward GGGAGGACTCAGACCTGGAT 105
Reverse CGGAATTTGGCAGTTTGGGG
Tnf-α Forward TAGCCCACGTCGTAGCAAAC 136
Reverse ACAAGGTACAACCCATCGGC
Vegf Forward ACTGGACCCTGGCTTTACTG 74
Reverse CTCTCCTTCTGTCGTGGGTG
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3.2.7 Immunofluorescence
Frozen tissue sections were labeled as previously described in [157]. Antigen retrieval
was performed by using 1% sodium dodecyl sulfate (SDS) in 0.01M PBS (5 min at
room temperature) or by heat antigen retrieval method. Briefly, sections were washed
with 1X PBS, post-fixed with 4% PFA, permeabilized with methanol. Sections were
then incubated in 10mM sodium citrate buffer at 65◦C for 45 min, allowed to cool at
room temperature (RT) for 20 min, rinsed in deionized (DI) water 3X and washed
in PBS once. To reduce autofluorescence, slides were then incubated 1% sodium
borohydride in PBS for 2 mins at RT. Slides were then blocked with 10% serum
(goat or donkey) in 1XPBS with 0.25%TritonX-100 for 1 h followed by primary an-
tibody diluted in blocking buffer overnight at 4◦C. Slides were then incubated with
Dylight conjugated secondary antibodies (1:800; Jackson Immunoresearch) or Alexa
flour (1:500; Invitrogen) conjugated secondary for 1 h at RT in the dark, washed
with 1X PBS, incubated with Hoechst staining solution (2 µg/ml in PBS) and then
mounted with Aqua Polymount (Polysciences).
Biotin-streptavidin amplification was done by incubating slides with biotinylated an-
tibody (1:500; Vector Labs) for 1 h at RT followed by Dylight conjugated to strep-
tavidin (1:100; Vector Labs) for 1 h at RT, in lieu of Dylight or Alexa flour conju-
gated secondary antibodies. For co-labeling involving primary antibodies made in the
same host, tyramide signal amplification was performed as per manufacturers proto-
col (Perkin Elmer). For primary antibodies made in mouse, reagents from the mouse
on mouse kit (Vector Labs) were used for blocking and primary antibody dilution.
Labeled slides were imaged using Olympus Fluoview FV 1000. Antibodies used for
immunofluorescence are listed in Table 3.2.
Cell counts were performed using the cell counter plugin of ImageJ. 40x images (n=9)
of retinal sections labeled with SOX9, CALBINDIN, CHX10 and BRN3A and 60X
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image of retinal flatmounts (n=8) labeled for G α TRANSDUCIN were used for cell
count analysis. Retinal thickness was measured on cross section of retina 200 µm
away from the optic nerve.
3.2.8 Western Blotting
Extraction of proteins from retinal tissue was performed using lysis buffer as previ-
ously described in [157]. Briefly, retinal tissue was homogenized in PBS and cen-
trifuged at 13,000 rpm, 4◦C for 10 min. The supernatant was discarded and the
pellet incubated with lysis buffer (150mM NaCl, 50mMTris pH 8.0, 2mM EDTA, 5µl
TritonX-100; 100mM PMSF and protease inhibitor cocktail, RPI corp.) for 20 min at
4◦C. The samples were centrifuged at 13,000 rpm, 4◦C for 10 min and total protein
was estimated using BCA protein assay kit (ThermoScientific).
Forty µg of protein was loaded onto 4-20% SDS precast gels (Expedeon), placed
in a Biorad gel run apparatus and run at 150V for 1 h. Proteins were transferred
onto a PVDF membrane, which was blocked with a 5% milk in tris buffered saline
tween 20 (TBST) at RT for 1 h on a shaker. The blots were incubated with primary
antibody diluted TBST at 4◦C overnight on a shaker. The following day, the blots
were washed in TBST and incubated with HRP conjugated secondary diluted 1:5000
in TBST for 1 h at RT. Blots were washed in TBST, incubated with super signal
west femto chemiluminescent substrate (ThermoScientific) and visualized on x-ray
film. β-TUBULIN was used as a loading control and the concentrations of antibodies
used are listed in Table 3.2.
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Table 3.2.
List of antibodies used
Antibody Company IHC con-
centration
Flatmount
concentra-
tion
Western
blot con-
centration
BRN3A Chemicon 1:250
CALBINDIN Sigma 1:250
GFAP Dako (poly-
clonal)
1:250 1:100
GFAP Dako (mono-
clonal)
1:1000
GαT SantaCruz 1:100
IBA1 Wako 1:500 1:250
NEUROCAN R&D 1:100
PU.1 Cell signaling 1:100
phosphoSMAD
1/5/8
Cell Signaling 1:50
phosphoTAK1 Abcam 1:500
S100β Abcam 1:300 1:1000
CHX10 Exalpha 1:500
SOX2 SantaCruz 1:250
SOX9 Millipore 1:500
TXNIP SantaCruz 1:250
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3.2.9 ELISA
Enzyme linked immunosorbent assay (ELISA) for IFN-γ was performed on media
from treated cells in vitro or from whole mouse retina protein lysates using the mouse
IFN-γ ELISA kit (Cat # ENEM1001, ThermoScientific) as per manufacturers proto-
col.
3.2.10 Retinal Flatmounts
Preparation of retinal flatmounts and immunolabeling was done as described in [177].
Briefly, enucleated eyes were washed in 1X PBS, fixed in 4%PFA for 15 min, trans-
ferred to 2X PBS on ice for 10 min followed by retina isolation. Four to five radial
incisions were made in the retina to create a petal shape. Excess PBS was absorbed
and retinas were transferred to cold methanol (-20◦C) for 20 mins. The tissue was
washed with 1X PBS and blocked in Perm/Block solution (1XPBS, 0.3% TritonX-
100, 0.2% bovine serum albumin and 5% donkey or goat serum). Tissue was then
washed in PBSTX (1XPBS, 0.3%TritonX-100) and incubated with primary antibody
(Table 3.2) overnight at 4◦C. On the following day, the tissue was washed in PBSTX,
incubated with secondary antibody, washed, incubated with Hoechst solution and
mounted onto a slide with Aqua Polymount (Polysciences, Inc). Labeled slides were
imaged using Olympus Fluoview FV 1000.
Morphological analysis of labeled microglia (n=4 per timepoint) for changes in area
and number of branches was performed using the Scholl analysis plugin in Fiji image
analysis software (Ferreira et al. 2014). Briefly, the flatmount image was loaded on
to the Fiji software and converted to binary. To calculate the area of the cell, the
”Measure plugin was selected from the Analyze options. To determine number of
branches, a center of analysis was defined via the straight line method. This line
was drawn from the center of the cell to the end of the longest branch to define a
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valid Startup ROI. The program was run on the default parameters with the starting
radius set at 10 pixels.
3.2.11 Statistical Analysis
Statistical analysis was performed via unpaired Studentss t-test using SPSS software
(IBM) between control/vehicle and treated groups for RT-qPCR, cell counts and
microglia morphology. RT-qPCR and densitometries from PLX and control mice in-
jected with vehicle or BMP7 was analyzed via one way ANOVA with Tukeys test for
post hoc analysis. p<0.05 were considered to be statistically significant.
3.3 Results
3.3.1 BMP signaling in retinal microglia
Previous studies have shown that BMP7 triggers reactive gliosis of the retinal macroglia.
Both the canonical as well as the non-canonical BMP-MAPK pathways were active
in the retinal Mu¨ller cells and astrocytes following BMP7 treatment (Dharmarajan
et al. 2014). However, the mechanism by which BMP7 triggered gliosis remains
unclear. To determine if any of these pathways were activated in the microglia of
control- or BMP7-treated retina, double-label immunohistochemistry was performed
using antibodies to phospho SMAD 1/5/9 (pSMAD), phospho TAK1 (pTAK1), and
PU.1 on adult retinas following intravitreal injection of vehicle- or BMP7- (Figure
3.1). In both vehicle- (Figure 3.1A–D) and BMP7-treated retinas (Figure 3.1E–H),
sections showed nuclear co-labelling with PU.1 and pSMAD. In contrast, pTAK1 was
localized primarily to the nuclei of GCL of vehicle-injected retinas with no apparent
co-localization with PU.1 (Figure 3.1I–L), but co-labeled PU.1+ cells in the BMP7-
treated retinas, in addition to other cells in the INL and GCL (Figure 3.1M–P).
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Fig. 3.1. pSMAD and pTAK1 are localized to retinal microglia (Continued on next
page).
There was also a striking increase in the localization of pTAK1 in the both inner
and outer plexiform layers of BMP7-treated retinas that was not apparent in vehicle-
treated retinas (Figure 3.1M–P). Retinal sections were also co-labeled with IBA1 and
pTAK1 or pSMAD to show localization in microglia (Figure 3.2). Negative controls
showed no label (Figure 3.3).
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Fig. 3.1. pSMAD and pTAK1 are localized to retinal microglia. Reti-
nal sections from P30 mouse injected with vehicle or BMP7 24 h post-
injection were double-labeled with antibodies that label microglial
nuclei (PU.1) and phospho SMAD 1/5/9 (pSMAD; A–H) or phospho
TAK1 (pTAK1; I–P). Thin plane confocal microscopy images with y,z
(strips to right of the panel) and x,z planes (strips at the bottom of the
panels) shown in (D), (H), (L), and (P). pSMAD-labeled cells were
primarily found in the GCL in the vehicle-treated retina, with some
co-localization with the nuclear microglial marker PU.1 (A–D). The
BMP7-injected retina had an increase in pSMAD expression in the
INL as well as substantial co-localization with PU.1 (E–H). In con-
trast, vehicle-injected retina showed pTAK1 expression in the GCL
with little to no PU.1 co-localization (I–L), while the BMP7-injected
retinas showed increased levels of pTAK1 levels in the INL, as well
as significant co-localization with PU.1 (M–P). Magnification bar in
A=50 µm, for images (A–P).
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Fig. 3.2. Expression of BMP signaling molecules in microglia in vehicle and BMP7-
injected retinas (Continued on next page).
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Fig. 3.2. Expression of BMP signaling molecules in microglia in ve-
hicle and BMP7-injected retinas.Retinal sections from P30 mouse in-
jected with vehicle or BMP7 24 h postinjection were double-labeled
with antibodies that labels microglia cytoplasm (IBA1) and phospho
SMAD 1/5/9 (pSMAD; A–F) or phospho TAK1 (pTAK1; G–L). Thin
plane confocal microscopy images with y,z (strips to right of the panel)
and x,z planes (strips at the bottom of the panels) shown in C, F, I
and L. pSMAD-labeled cells were primarily found in the GCL in the
vehicle-treated retina, with some co-localization with the cytoplasmic
microglial marker IBA1 (A–C). The BMP7-injected retina had an
increase in pSMAD expression in the INL as well as substantial co-
localization with IBA1 (D–F). Vehicle-injected retina showed pTAK1
expression in the GCL with little to no IBA1 co-localization (G–I),
while the BMP7-injected retinas showed increased levels of pTAK1
levels in the INL, as well as significant co-localization with IBA1 (J–
L). Magnification bar in A=50 µm, for images (A–L).
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Fig. 3.3. Negative control of immunofluorescence labels. Retinal sec-
tions from P30 mouse labeled with rabbit immunoglobulin G (Rbt
IgG; A–C, D, F), mouse IgG (Mse IgG; E, F), and sheep IgG (G, H)
to determine background fluorescence. Images of sections labeled with
the nuclear stain, Hoechst merged with the images of green and red
channels are shown in C and F. Panels A–C represent sections, which
were labeled with IgG following the procedure used for tyramide am-
plification when using two antibodies for the same species. Images in
D–F represent sections co-labeled with rabbit and mouse IgG. Images
A–C are negative controls for Figure 3.1 and Figure 3.2. Images D–F
are negative controls for sections labeled with GFAP, S100β, CAL-
BINDIN, BRN3A, CHX10, SOX9, and IBA1. Images G and H are
negative control sections for NCAN-labeled slides. Magnification bar
in A=50 µm, for all panels.
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3.3.2 BMP7 induces inflammatory changes in vivo
To determine whether BMP7 regulated inflammatory signals that could then ei-
ther trigger or enhance the gliosis response, BMP7-treated retinas were analyzed
for mRNA levels of pro-inflammatory markers (Figure 3.4A). For the analyses of
mRNA levels, values plotted in graphs were all relative to control levels which were
set to a value of 1.0; hence, increases in mRNA levels in comparison to controls are
bars above a level of 1.0, while a decrease is represented by bars below the level
of 1.0. Three days post-injection, increases of 1.5-fold or more in mRNA levels of
Tnf-α, Il-1β and Ifn-γ were present. However, larger increases were evident in mul-
tiple factors 7 days post-injection, including Gm-Csf, Csf, Ifn-α, Ifn-γ, Il-6, Vegf,
thrombospondins-1 and-2 (Thbs1 and Thbs2) and Cd68. We also observed more than
a two-fold increase in microglial marker Iba1 and Irf8, markers for activated microglia.
To determine if the increases in pro-inflammatory markers present in BMP7-treated
retinas were mediated by retinal microglial cells, the effect of BMP7 treatment on
isolated mouse retinal microglial cells in vitro was observed using RT-qPCR. mRNA
levels were investigated in microglial cells incubated with vehicle or BMP7 for 3, 6,
12, or 24 h (Figure 3.4B). Again, changes in mRNA levels relative to controls were
plotted, where a value of 1.0 indicates levels of control mRNA. Following 3 h of in-
cubation with BMP7, only levels of Ifn-γ were 1.5-fold greater, whereas at 6 h the
average mRNA levels of Gm-csf, Ifn-γ, Csf1, Tnf-α and Il-6 and Cd68 were increased
to 1.5-fold above control or greater (Figure 3.4B). By 24 h of incubation, many of
the molecules levels were decreased in comparison to the 6 h time point; however,
Ifn-γ and Thbs2 were increased in comparison to control and 6 h mRNA levels. As
a positive control for inflammation, microglia were incubated with LPS for 3 h (Fig-
ure 3.4C). To determine if the changes in RNA levels are being translated to protein,
we determined IFN-γ levels by an ELISA using medium from microglial cells incu-
bated with BMP7 for 24 h and whole retinal lysates from mice treated with vehicle
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Fig. 3. 4. BMP7 injection triggers inflammatory changes in the mouse retina (Con-
tinued on next page).
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Fig. 3.4. BMP7 injection triggers inflammatory changes in the mouse
retina. Expression levels of a panel of pro-inflammatory markers were
analyzed by RT-qPCR in RNA samples from mouse retina injected
with vehicle or BMP7, harvested 3 and 7 days post-injection (A). At
3 days post-BMP7 injection, about a 2-fold increase in RNA levels,
relative to the vehicle controls, was observed in levels of Ifn-γ, Tnf-α,
and Il-1β. Seven days post-BMP7 injection, 2-fold increase in levels
was observed in Csf, Vegf, Thbs1, and Thbs2, and greater than 3-fold
increase in Gm-csf, Ifn-γ, Il6, and CD68 RNA levels relative to the
vehicle-injected control. Mouse retinal microglial cells treated with
BMP7 for 3, 6, 12, and 24 h were also analyzed for changes in RNA
levels of inflammatory markers (B), with LPS treatment used as a
positive control (C). In vitro treatments showed a significant increase
in Ifn-γ levels at the 3-h time point. At 6 h post-BMP7 treatment,
mRNA levels of Gm-csf, Ifn-γ, Csf, Tnfα, Il-6 and Cd68 were in-
creased to 1.5-fold or greater. By 12 h, we observed no significant
differences between BMP7 and vehicle-treated samples. At the 24-h
time point, however, we observed significant increases in the levels of
Ifn-γ and Thbs. The LPS-treated microglia showed a relative increase
in most of the markers, with significant increases observed in levels
of m-csf, Ifn-γ, Il-6 and Thbs2 (C). Protein levels of IFN-γ was also
determined via ELISA (D). We observed a 2-fold increase in levels in
medium from microglial cells incubated with BMP7 for 24 h and in
protein from whole retinal tissue from mice injected with BMP7 for 3
days, when compared to their respective vehicle control. Protein from
7 days BMP7-injected retina showed a 5-fold increase in protein lev-
els compared to the vehicle control. Data shown in graphs represent
relative expression levels of RNA or protein of BMP7 or LPS-treated
samples to their respective vehicle control. Bars above a level of 1.0
(solid black line) represent an increase in mRNA levels while bars be-
low the level of 1.0 represent a decrease in mRNA levels relative to
the corresponding vehicle control. Statistical analysis was performed
by unpaired Students t-test. Significant difference from the respective
vehicle controls ∗ =p value <0.05.
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or BMP7 (Figure 3.4D). Values plotted in graph are relative to the respective vehicle
controls; hence, increases in mRNA levels in comparison to controls are bars above
a level of 1.0, while bars below the level of 1.0 represent a decrease. We observed
a two-fold increase in the IFN-γ protein levels in the astrocytes and microglial cell
medium, and a five-fold increase in IFN-γ protein level was detected in retinal lysates
7 days post-treatment with BMP7 compared with vehicle.
Changes in morphological characteristics of microglia following control and BMP7
treatments were subsequently investigated. It has been reported by other investi-
gators that activated microglia increase in area with an increase in branch points
(Kreutzberg 1996). Retinal flatmounts of 1 day BMP7- and vehicle-treated retinas
were labeled with IBA1 and analyzed for average cell area and number of branch
points in cellular processes (Figure 3.5A, B). Graphs show relative changes in the
area and number of branches (Median intersections output from the Sholl analysis).
Morphological analysis revealed that the BMP7-treated retinas contained microglia
with a larger area in comparison to vehicle-treated retinas, and a decrease in the
number of branches (Figure 3.5C).
3.3.3 Activated microglia secrete factors that induce gliosis
We have observed that BMP7 is able to activate retinal microglia in vitro and in
vivo (Figure 3.4 and 3.5, respectively). To determine if microglia secrete factors that
trigger reactive gliosis in vitro, we used conditioned medium obtained from mouse
microglia cultures treated with vehicle (vehicle conditioned media) or BMP7 (BMP7
conditioned media) for 24 h, and used for treatment of mouse retinal astrocytes (Fig-
ure 3.6B, C, D). Graphs represent mRNA levels in astrocyte cultures treated with
BMP7 conditioned media relative to cultures treated with vehicle conditioned me-
dia; pretreated with DMSO or LDN193189. Retinal astrocyte cells were incubated
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Fig. 3.5. BMP7 alters microglial morphology. Retinal flatmounts
from 1 day BMP7- and vehicle-injected retina were labeled for IBA1
(A, B) and analyzed for morphological changes. An increase in the
area of the microglia was observed when compared to the vehicle
control (C). Number of branches and branch length were also assessed
for the treated cells, and increase in the number of branches was
observed with a decrease in the branch length of the cells incubated
with LPS or BMP7 when compared to the vehicle control (C). Data
shown in c represent relative change in area and number of branches
in BMP7-treated samples to the vehicle control. Bars above a level of
1.0 (solid black line) represent an increase while bars below the level
of 1.0 represent a decrease in the parameter measured, relative to the
corresponding vehicle control. Statistical analysis was performed by
unpaired Students t-test. Significant difference from the respective
vehicle controls ∗ =p value <0.05. Magnification bar in A=50 µm,
for images (A, B).
90
for 24 h with microglial cell conditioned medium and were assessed for changes in
markers associated with gliosis. To reduce the possibility that the BMP7 added to
the microglial medium might directly affect the astrocytes, an inhibitor of BMP re-
ceptors, LDN193189 was added to the conditioned medium (Figure 3.6D). RT-qPCR
analysis showed a statistically significant increase in expression of gliosis markers
Gfap, S100β, Gs, Egfr and Pcan 1.5-fold above that of astrocyte cells treated with
DMSO and vehicle-treated conditioned media (Figure 3.6B). When BMP inhibitor
was added to the astrocyte medium prior to addition of conditioned medium from
microglia, statistically significant increases were detected in Gfap, Gs, S100β, Egfr
and Tlr4 (Figure 3.6D). Treatment of retinal astrocytes with DMSO or LDN alone,
or with conditioned media in presence of DMSO were used as experimental con-
trols (Figure 3.6A, C). We did not observe any changes when cells were treated with
LDN alone (Figure 3.6A). Treatment of retinal astrocytes with conditioned media
in presence from DMSO showed similar changes in expression as cells treated with
conditioned media alone (Figure 3.6C).
3.3.4 PLX ablates retinal microglia
To further investigate the role of microglia in BMP7-mediated gliosis, a means to
ablate microglial cells within the retina was sought. Previous reports have shown
colony stimulating factor receptor 1 (CSFR1) inhibitor, PLX3397, to selectively ab-
late microglia in the brain (Elmore et al. 2014). We have used a variant of the drug,
PLX5622, supplied by Plexxikon Inc. in chow form to determine its effect on retinal
microglia. Starting at postnatal day 30, mice were switched to control chow or chow
containing 1200 ppm PLX. The mice continued treatment with the inhibitor-laced
chow until sacrificed 7, 14, or 21 days later. Retinal flatmounts from control and
PLX mice were isolated 7, 14 and 21 days, and labeled for IBA1 and GFAP (Fig-
ure 3.7). Although no apparent change in GFAP was observed (Figure 3.7B–E), there
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Fig. 3.6. Activated microglia secrete factors that trigger retinal glio-
sis. Conditioned medium from microglial cells incubated with BMP7
or vehicle for 24 h was added to the medium of the retinal astrocytes,
directly or pretreated with LDN193189 (C, D). RNA was isolated
from these cells 24 h posttreatment and analyzed via RT-qPCR for
a panel of gliosis markers. Statistically significant increase in lev-
els of Gfap, Gs, S100β, Pcan, Egfr and Tlr4 was observed in as-
trocytes incubated with conditioned medium added directly or pre-
treated with LDN193189 (C, D). Cells treated with DMSO (carrier
for LDN193189) or LDN only (A) or cells pretreated with DMSO
and conditioned medium from BMP7 or vehicle-treated microglia (B)
were used as experimental controls. Data shown in graphs represent
relative expression levels of RNA in retinal astrocyte cells treated
with LDN193189 relative to DMSO (A) or with conditioned media
from BMP7-treated microglial cells relative to retinal astrocyte cells
treated with conditioned media from vehicle-treated microglia (B–D).
Statistical analysis was performed by unpaired Students t-test. Sig-
nificant difference from the respective vehicle controls ∗ = p value
<0.05.
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was a clear decrease in the number of IBA1+ cells 7 days after starting the PLX diet,
and IBA1 immunoreactivity was completely lost by 14 days (Figure 3.7F–M). Reti-
nal tissue sections from these mice were also analyzed for ganglion cells (BRN3A),
bipolar cells (CHX10), Mu¨ller glia (SOX9) and horizontal cells (CALBINDIN) (Fig-
ure 3.7A–D, F–I). Cell counts for labeled cells showed no statistically significant
change between the control and PLX treated mice (Figure 3.8K). Retinal flatmounts
of PLX and vehicle treated retinas were also labeled with Gα transducin to label
photoreceptors (Figure 3.8E, J). Cell count of labeled images showed no statistically
significant change in cell numbers (Figure 3.8L). Thickness of retinal sections of the
control and PLX treated mice also showed no change (Figure 3.8M).
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Fig. 3.7. PLX ablates microglia in the retina. Mice were fed with
chow-containing PLX or vehicle dye to determine ablation of microglia
in the retina. a Schematic describing the time points for which the
mice were fed with chow-containing PLX, following which eyes were
harvested. Retinal flatmounts prepared from the eyes harvested at
7, 14, and 21 days were labeled for GFAP or IBA1 (B–I). Insets in
B–E indicate the flatmount outline and from where the images (B–I)
was taken. While GFAP did not show any difference between the
stages examine (B–E), there was a significant decrease in IBA1 label
in mice kept on PLX diet for 7 days (F, G). By 14 days, no IBA1 label
was found in the retinal flatmount and this absence persisted into the
21-day time point (H, I). Retinal sections control and PLX-treated
mice labeled for IBA1 to show loss of microglia in the deeper layers
of the retina (J–M). Magnification bar in B=50 µm, for images B–I.
Magnification bar in J=50 µm, for images J–M.
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3.3.5 Microglial ablation reduces BMP7-mediated gliosis
To determine if microglia were involved in BMP7-mediated gliosis response, mice with
ablated microglia (PLX mice) were injected intravitreally with vehicle or BMP7, and
mRNA levels of pro-inflammatory markers or gliosis-related molecules were deter-
mined by RT-qPCR 7 days (d) post-injection. As in previous graphs, levels of mRNA
are relative to levels in the respective vehicle-treated mice. Mice kept on control
chow and treated with BMP7 showed an increase in levels of inflammatory markers
including Gm-csf, Ifn-γ, Il-6 and Iba1, and gliosis markers including Vim, Gfap, Egfr,
Mmp9, Lcn2 and Txnip (Figure 3.9A, B). Analysis of inflammatory markers of mice
on PLX chow and treated with BMP7 via RT-qPCR also showed only modest in-
creases in levels of Il-1β and Vegf compared to vehicle control (Figure 3.9B). mRNA
levels of Gm-csf, Ifn-γ, Il-6, Cd68 and Iba1 dropped drastically when microglia were
not present (Figure 3.9B). RT-qPCR analysis of PLX mice 7 d post-BMP7 treatment
showed no increase in mRNA levels of gliosis markers compared to the PLX vehi-
cle controls (Figure 3.9A). Markers indicative of gliosis were further investigated by
examining patterns of immunoreactivity for GFAP, S100β, and NCAN (Fig. 3.9A,
B). Three days following vehicle or BMP7 injection, the PLX mice showed similar
levels of GFAP and S100β label in control and PLX mice (Figure 3.10 A(a, b, d, e,
g, h, j, k)). However, 7 d post-injection, the PLX mice showed decreased GFAP and
S100β label in BMP7-injected PLX retinas (Figure 3.10B (j, k)), when compared to
the control BMP7-injected retinas (Fig. 3.9B (d, e)). NCAN immunofluorescence
label did not diminish following PLX treatment in comparison to controls at either
3 d (Figure 3.10A (f, l)) or 7 d post-injection (Figure 3.10B (f, l)). Moreover, levels
of NCAN were increased in vehicle-injected eyes at both 3 and 7 d of PLX-treated
mice in comparison to vehicle-injected eyes of control-treated mice (compare Fig A
(c and i) and Fig B (c and i)), supporting a potential role for microglia in extracel-
lular matrix remodeling. Gliosis markers showed similar label in uninjected mice in
comparison to the 3 day and 7 day vehicle injected mice (Figure 3.11). Protein levels
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of gliosis markers GFAP, S100β, and TXNIP were also quantified using western blot
(Figure 3.12).
3.4 Discussion
Our lab previously showed that BMP7 is able to trigger reactive gliosis in the retina.
Here we show that the Mu¨ller cell gliosis triggered by BMP7 is an indirect effect re-
sulting from microglial activation to a pro-inflammatory state. Following exposure to
BMP7, microglia upregulated at least two molecules, IFN-γ and IL-6, both of which
have been shown in previous studies to trigger gliosis (Lee et al. 1993; Yong et al.
1991; Corbin et al. 1996; Chakrabarty et al. 2010; Chiang et al. 1994). The CSFR1
inhibitor PLX was used to specifically target and ablate retinal microglia without af-
fecting numbers of other retinal cells, in order to show that the BMP7 triggers gliosis
through microglial activation. We observed that BMP7 injection into retinas lacking
microglia produced an abated inflammatory response and a complete loss of gliosis,
suggesting an important role for the microglia in mediating the gliosis response.
3.4.1 BMP pathway in retinal disease
BMPs have been previously shown to be regulated in injury and disease models of
the CNS and retina [111,129,161,178]. The BMP receptors type 1A and 1B regulate
hypertrophic and scarring responses of astrocytes following spinal cord injury [81]. In
the retina, BMP signaling components phospho SMAD 1/5/8, have also been shown
to be upregulated following NMDA induced injury and promote retinal ganglion cells
survival [78]. We observed an increase in pTAK1 label in IBA labeled cells in the
retina, as well as in other cells of the inner nuclear layer. Increases in expression
of pTAK1 in neurons has been previously reported in the brain following cerebral
ischemia and is known to be expressed in axonal arbors of sensory neurons [179,180].
BMPs have also been shown to be important in retinal cell proliferation and regen-
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Fig. 3.10. Effect of BMP7 on gliosis in absence of microglialocalization
of gliosis markers. Mouse retinal sections from eyes injected with
vehicle or BMP7 were labeled for gliosis markers GFAP (A, B (a,
d, g, j)), S100β (A, B (b, e, h, k)), and NCAN (A, B (c, f, j, l)).
Mice kept on the PLX diet did not show an increase in label for the
gliosis markers GFAP and S100β BMP7 or vehicle-injected retina 3
and 7 days postinjection (A, B (g, h, j, k)). NCAN label appeared
to be similar in the BMP7 injected and the respective age-matched
vehicle controls in mice kept on the PLX chow (A, B (i, l)). Mice
kept on the control chow and injected with BMP7 clearly showed
an increase in GFAP, S100β and NCAN levels 7 days postinjection,
when compared to their respective vehicle control (B (a–f)). Three
days postinjection, there is an increase in GFAP and NCAN label in
BMP7-injected retinas in comparison to the respective vehicle control-
injected retinas (A (a, c, d, f)). When comparing mice kept on control
chow or the PLX chow, there is an increase in GFAP and S100β label
in the mice kept on control chow in comparison to the mice kept on
the PLX chow, 7 days post BMP7 injection (B (d, e, j, k)). GFAP
and S100β label in mice kept on control chow and PLX chow appears
to be similar in the BMP7-injected retinas, 3 days postinjection (A
(d, e, j, k)).
eration in the chick retina [181]. Ueki and Reh (2013) showed that SMAD upregula-
tion was essential in mediating EGF dependent Mu¨ller glial cell proliferation in the
mouse [135]. The presence of BMPs in disease states is consistent with a potential
role for them playing a role in retinal gliosis.
3.4.2 Activated microglia drive retinal gliosis
We had previously reported that BMP7 was able to trigger gliosis in retinal glia in
vitro and in vivo. However, we observed a higher response in the in vivo model,
which suggested there may be other cells involved in this response. Microglia are
the resident macrophages in the retina. Similar to the macro glia, these cells also
undergo activation. Their activation has been observed in various disease and injury
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Fig. 3.11. IF label of retinas for GFAP, S-100-β, and NCAN in P30
uninjected and 3 and 7 days vehicle-injected retinas.Retinal sections
from uninjected P30 mouse, vehicle-injected P30 mouse, obtained 3
and 7 days post-injection, labeled for GFAP (A, D, G), S100β (B, E,
H), and NCAN (C, F, I). Label for all three markers appears to be
similar in the uninjected and the vehicle-injected retinas. Magnifica-
tion bar in A=50 µm, for images A–I.
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Fig. 3.12. Protein levels in PLX-treated mice. Protein isolated from
control and PLX-treated mice injected with vehicle or BMP7 changes
in protein levels of gliosis markers GFAP, S100β, and TXNIP, with
β-TUBULIN used as a loading control.GFAP showed elevated levels
in the BMP7-injected control mice, while PLX mice had GFAP levels
similar to the vehicle injection. S100β was elevated in the 3 and 7
days BMP7-injected PLX mice as well as in the 7 days BMP7-injected
control mice, compared to the respective vehicle controls. TXNIP
levels did not change in the control and PLX mice injected with vehicle
or BMP7 3 days post-injection. Seven days post-injection, TXNIP
levels did increase in the control BMP-injected mice, while no such
change was observed in the PLX mice. No statistical significance was
observed in the densitometric analysis (B) of blots from (A).
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models, such as, retinitis pigmentosa, diabetic retinopathy, retinal detachment and
glaucoma [182–186]. Activated microglia change morphology from a ramified cell to
an amoeboid cell, along with changes in expression of cell surface markers, such as
the cluster of differentiation molecule 11b (CD11b), CD68, major histocompatibility
complexes (MHC), scavenger receptors, TLR, and secreted actors such as RANTES,
interferon, interleukins and TNFα. These changes serve to enhance the phagocytic
effect of the microglial cells as well as the cytotoxic effect on injured cells and foreign
pathogen [31, 187]. Mu¨ller glia also undergo activation following disruption retinal
homeostasis. The reactive Mu¨ller glia hypertrophy and upregulate expression of var-
ious growth factors, reactive oxygen species scavengers, protect neurons from excito-
toxicity and in some organisms, can regenerate retinal neurons. These changes serve
to protect the damaged retina. However, gliosis can also have detrimental effects by
remodeling the extracellular matrix and due to loss of normal glial functions which
are necessary for normal neuronal activity [42,46].
The retinal astrocytes and Mu¨ller glial cells exhibit similar responses to injury, such as
hypertrophy, upregulation of GFAP, VIMENTIN and GS, as observed in rat models
of retinal detachment and retinitis pigmentosa [124, 188, 189]. However, research has
also revealed that there are differences in the response of the two cells types. GFAP
upregulation was observed in Mu¨ller glia and not in the astrocytes in rats subjected
to episcleral vein cauterization [190]. Similarly, upregulation of GFAP was observed
in the Mu¨ller glial cells in retina subjected to laser induced ocular hypertension, while
the astrocytes of the contralateral control eyes also exhibited an increase in GFAP
and a change in the area covered by the astrocytes [191, 192]. The differences ob-
served may suggest distinct functional roles for the astrocytes and Mu¨ller glia, which
cooperate to restore retinal homeostasis.
Here we observed a decreased gliosis response in the retina following BMP7 treatment
in mice lacking microglia. We used a novel CSF1R inhibitor (PLX) to selectively ab-
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late microglia. Following microglial ablation, mice were treated with BMP7 to assess
gliosis in the retina. The inclusion of the inhibitor in the chow allowed its continual
application over a longer period of time, enabling the maintenance of a microglia-free
environment in the retina in which we could test the role of the microglia in BMP7-
mediated gliosis. Without continual application of the inhibitor, microglia could
repopulate the retina from one of two sources: 1) bone marrow-derived stem cells can
penetrate the blood-brain barrier and differentiate into microglia, or 2) residential mi-
croglia can proliferate and replace lost cells (Elmore et al. 2015; Jin et al. 2016). The
two sources of microglia are not equivalent; residential microglia primarily give rise
to microglia that display an M1 inflammatory phenotype, whereas the bone marrow-
derived cells give rise to microglia with an M2 anti-inflammatory phenotype [193].
At any rate, in order for us to test the role of BMP7 in indirectly triggering gliosis,
we had to maintain a microglial-free environment for the duration of the experiments.
3.4.3 BMP and inflammation
Activation of microglia and macroglia have been studied in various models. While
there are differences in the responses of the two glial populations, they do exhibit
similarities. These include regulation of inflammatory markers, regulation of anti-
gen presentation complexes, various factors such as IFN-γ, TNF-α, and toll like
receptor (TLR) [33, 42, 172]. While several different factors have been shown to
regulate macrophage and microglia activation, the effect of BMPs is still not com-
pletely characterized [59, 165, 174, 194]. BMP6 regulates expression of inflammatory
markers such as IL-6, IL-1β and nitric oxide synthase in macrophages [195–197].
In addition, more recent studies indicate that BMP exposure particularly leads to
the M2 or anti-inflammatory phenotype of the macrophages promoting tissue re-
pair [198–201]. Microglia are descendants of immature macrophages and are thought
to act as macrophages in disease and injury states [202]. In our studies, BMP7 in-
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creased the pro-inflammatory state of the microglia. Further studies are necessary to
determine if all microglia respond to BMP7 by increasing pro-inflammatory markers
or if this is a response unique to certain populations of microglia.
In this study, we observed that microglia showed an upregulation of inflammatory
markers in response to BMP7 treatment, indicative of activation. Furthermore, in
the PLX treated mice, the gliosis response was subdued in comparison to control
BMP7 treated retinas, suggesting that microglia are an essential mediator of retinal
gliosis. These results support our hypothesis that microglia are activated by BMP7,
which in turn regulate factors causing Mu¨ller cell gliosis.
In the PLX-treated mice (both vehicle and BMP7-injected), we also observe an in-
crease in neurocan levels in the retina. Mu¨ller glia secrete MMPs that regulate neu-
rocan levels in the extracellular matrix. In addition, microglia also secrete these
enzymes [203, 204]. Their upregulation has been observed in the CNS during in-
flammation in various injury models. Furthermore, microglia derived factors such as
TNF-α have also been shown to regulate MMP expression by the Mu¨ller glia [205].
Thus, we propose that the lack of microglia in the retina contributes to the increase in
neurocan by regulating MMP levels either directly or indirectly by regulating Mu¨ller
glia.
Comparing the mRNA and protein levels in the control and PLX injected retinas,
we observed a difference in expression patterns (Figure 3.7). Although the mRNA
levels of S100β and TXNIP was reduced in the BMP7-injected PLX mice, we did not
observe a similar change at the protein level. Non-correlation between mRNA and
protein levels has been noted in other studies [140, 142, 206, 207]. mRNA translation
and protein stability in the cell is regulated by multiple systems including, by mi-
cro RNAs (miRNAs), mRNA localization translational repression and protein stabil-
ity [144,207]. miRNAs have been previously reported to be regulated in neural tissue
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under conditions of stress [151,208,209]. Furthermore, BMPs can regulate translation
by regulating cytoplasmic polyadenylation element binding protein (CPEB) via the
TAK pathway [145, 210]. Further studies will be required to determine what path-
way(s) mediate this non-correlation between the mRNA and protein levels.
3.4.4 Microglia release inflammatory factors prior to formation of gliosis
We observed a decrease in expression of GFAP and S100β in mice kept on the PLX
diet and treated with BMP7. BMP7-treatment also revealed decreased RNA levels
of gliosis and inflammatory markers in PLX mice when compared to the mice kept
on the normal diet. Previously, it has been reported that microglia respond early to
changes in microenvironment and become activated. Bosco et. al showed that mi-
croglia become activated early in the retina, prior to any increases in the intra-ocular
pressure (IOP) in the DBA/2J mice [164]. Similarly, early activation of microglia has
also been observed and implicated in progression of Parkinsons disease [211]. Fur-
thermore, in the ocular hypertension mouse model studied in Gallego et. al 2012,
the authors, suggest that upregulation of MHC-II in microglia in the controlateral
eye regulated the morphological changes of retinal astrocytes [192]. Thus, we propose
that microglia respond to the BMP7 first and become activated. These activated
microglia upregulate factors, which in turn can trigger Mu¨ller cell gliosis. Consistent
with this notion our findings indicate the IFN-γ and other inflammatory factors were
upregulated as early as 3 h following incubation of microglial cells with BMP7 in
vitro, and these levels were further increased 6, 12 and 24 h post-incubation with
BMP7. In contrast, factors associated with gliosis do not begin to increase until 3 d
in vivo, with most markers increasing after 7 days.
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3.4.5 Potential factors regulating microglia mediated activation of Mu¨ller
glia
Previous studies looking into microglia and macroglia interactions have revealed sev-
eral secreted as well as membrane bound factors which could activate the macroglia,
such as IL-1β, IL-18, TGF-β and TNF-α [31, 59, 212]. Morphological changes and
increases in RNA levels of inflammatory markers in the microglia following BMP7
treatment indicate activation of the microglia. We observed in our analysis that
RNA levels of Ifn-γ, Il-6, Vegf and Thbs1 to be greater following Mu¨ller glia activa-
tion. Previously, Cotinet et.al 1997 and Goureau 1994 showed that IFN-γ can trigger
Mu¨ller glia to regulate TNF-α and nitric oxide (NO) [67, 213]. Similarly, IL-6 has
been shown to induce Mu¨ller glia derived progenitor cells in the injured zebrafish and
chick retina [70, 174]. We propose that BMP7 causes activation of microglia, which
leads to upregulation of factors such as IFN-γ and IL-6, which in turn trigger Mu¨ller
cell gliosis.
Our findings indicated an important role for microglia in Mu¨ller cell gliosis in the
murine retina. However, the mechanism and potential factors that play a role in mi-
croglia and Mu¨ller glia interactions are not known. Future studies will aim to identify
the potential role of IFN-γ and IL-6, upregulated by BMP7 in the retina, in microglia
function and gliosis.
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4. ROLE OF AMOT-YAP SIGNALING IN REGULATION
OF GLIOSIS
4.1 Introduction
Gliosis has been shown to involve a wide range of factors and pathways including
TGF-β, CNTF, LIF, Wnt and Notch. While gliosis is observed in all retinal injury
and disease models, studies have revealed different factors to be involved in its regu-
lation. In diabetic retinopathy, hyperglycemia can induce factors such as VEGF and
inflammatory factors such as TNF-α and IL from the Mu¨ller glia, which lead to the
activation of the glial cells and disease pathology, particularly by activating ERK sig-
naling in the Mu¨ller glia [214–216]. ERK signaling is also regulated during ischemia
and leads to Mu¨ller cell gliosis. In retinal detatchment, FGF2 and endothelin-2 (ET-2)
are known to regulate gliosis [217, 218]. In retinitis pigmentosa and similar photore-
ceptor injury models, TGF-β, CNTF and FGF regulate the gliosis response in the
retina [219–222]. Although many secreted factors are known to trigger gliosis, it is
not clear if these factors trigger gliosis through separate pathways or if they trigger
the activation of a common pathway which regulates gliosis.
The Hippo pathway, which mediates tissue homeostasis by regulating prolifera-
tion, growth and differentiation, has been shown to interact with pathways involved
in gliosis activation such as the Wnt, TGF-β, BMP and Notch. While, the Hippo
pathway has been identified as a regulator proliferation and differentiation in progeni-
tors in the zebrafish retina, its role in Mu¨ller glia activation has not been investigated.
The effector protein of the Hippo pathway is the yes activated protein (YAP). Ac-
tivation of the Hippo pathway leads to phosphorylation and activation of the core
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kinases (MST1/2 and LATS1/2), which then phosphorylate YAP, leading to degra-
dation, ubiquitination or cytoplasmic retention. The unphosphorylated YAP, in a
complex with transcriptional co-activator with PDZ binding motif (TAZ), is translo-
cated to the nucleus and binds to the transcription co-factor transcriptional enhancer
associated domain (TEAD) to bring about activation of genes associated with prolif-
eration, cell cycle progression and inhibition of apoptosis [84].
The Hippo pathway is regulated by cell-cell and cell-ECM contact via Rho GTPases,
growth factors via G-protein coupled receptors, cell polarity proteins including an-
giomotins (AMOTs) as well as stress signals. Cell interaction with ECM as well as
low cell density induce YAP/TAZ nuclear localization by inhibiting phosphorylation
of LATS kinases [223, 224]. Alternatively, at high cell density, the core kinases are
phosphorylated preventing the nuclear localization of YAP [225, 226]. Similarly me-
chanical signals such as stretching also regulate the hippo pathway through F-actin,
directly by phosphorylating kinases MST and LATS or indirectly via GPCRs [86].
Growth factors regulate the hippo pathway by inhibiting phosphorylation of LATS,
through activation of GPCRs (example Wnts) or through phosphatidyl inositol 3-
kinase (PI3K; example EGF) [227,228]. Tight junction and adherens junction proteins
such as α-catenin, NF2, protein tyrosine phosphatase-1 and angiomotins (AMOTs)
also regulate YAP localization by regulating the kinases or by directly binding YAP
and sequestering it to the cytoplasm [59,229,230].
Angiomotins (AMOTs) are a family of cytosolic proteins found in tight junctional
complexes. The PPxY motif and WW domain in the AMOTs and YAP, respectively,
mediate the interaction of the two proteins, binding AMOTs with YAP. This local-
izes YAP to the tight junctions thereby inhibiting the Hippo pathway. The AMOT
family consists of AMOT, which includes isomers AMOT p130 and the N terminal
truncated version AMOT p80, AMOT like 1 and AMOT like 2. The AMOT p80 is
the dominant negative form of AMOT and binds to AMOT p130, preventing the cy-
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toplasmic localization of the AMOT p130 YAP complexes [231–233]. Thus, AMOTs
are important mediators of the cell-cell interaction cues to the Hippo pathway. Here
we hypothesize that AMOTs are down regulated during gliosis in the Mu¨ller glia,
leading to nuclear localization of YAP, which in turn regulates the hypertrophic and
proliferative gliosis responses. Furthermore, YAP in the retinal glia interacts with
transcription factors such as STATs, SMADs and β-catenin, which are downstream
of factors such as CNTF, TGF/BMP and Wnts, respectively, and regulate the gliosis
response.
4.2 Methods
4.2.1 Cell culture
Mouse retinal astrocytes were isolated and maintained as previously described in
[116]. Confluent cell culture plates were treated with 0.1µg/ml YAP/TEAD inhibitor,
verteporfin (VP) or 1µl/ml DMSO. Cells allowed to grow for 24 h following which
RNA was isolated from the cells and subsequently used for RT-qPCR analysis.
4.2.2 Intraocular injections
Postnatal day 30 (P30) C57BL/6J mice were anesthetized with ketamine/xylazine
cocktail and injected intravitreally with 1 µl 20ng/µl VP in one eye and 1µl/ml DMSO
in the contralateral eye or 1µl 150ng/µl IFN-γ and 1µl PBS in the contralateral eye.
Mice were also co-injected with 1µl 150ng/µl IFN-γ and 1 µl 20ng/µl VP or 1µl PBS
and 1µl/ml DMSO in the contralateral eye. Injections were performed using a manual
microsyringe and pulled glass micropipettes as previously described in [234].
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4.2.3 Tissue processing and immunofluorescence
Eyes from euthanized C57BL/6J mice were enucleated, washed in PBS, and either
fixed in 4% paraformaldehyde (PFA) for immunofluorescence (IF) or dissected to
isolate the retina for preparation of RNA and/or protein. For IF analysis, enucleated
eyes were washed and fixed in 4% PFA, incubated in ascending series of sucrose, and
frozen in a sucrose OCT solution as previously described in Dharmarajan et al., 2014.
Thick sections (12 µm) were cut using Leica CM3050S cryostat onto Superfrost Plus
slides (ThermoScientific) and stored at 80◦C until use. Frozen sections were labeled as
previously described in (Dharmarajan et al. 2017). Briefly, sections were fixed in 4%
PFA for 20 mins, followed by permeabilization in methanol for 10 mins. Slides were
washed in 1x PBS and blocked in 0.25% triton x 100 PBS with 10% serum (donkey or
goat) for 1 h at room temperature (RT). Slides were incubated with primary antibody
(YAP 1:500, abcam; GFAP 1:250, dako; GLUTAMINE SYNTHETASE 1:300,
Millipore; SOX9 1:300, santa cruz; S100β 1:300, abcam; AMOT 1:500, Dr.Clarke
Wells laboratory, IUSM) diluted in blocking buffer overnight at 4◦C, washed in PBS
and incubated with secondary antibody diluted in PBS for 1 h at RT in dark. The
slides were then washed in PBS, incubated with hoecsht nuclear staining solution for
5 min at RT in dark and mounted with aqua polymount.
4.2.4 Western blotting
Extraction of proteins from retinal tissue was performed using RIPA lysis buffer as
previously described. Total protein was estimated using the BCA protein assay kit
and 40µg of total protein was loaded onto a 4-20% SDS precast gel and transferred
to a PVDF membrane, as previously described. Membrane blots were blocked in 5%
milk in TBST for 1 h at RT on a shaker and incubated with primary antibody (AMOT
1:500; AMOTL1 1:500; β-TUBULIN 1:1000, Sigma; GFAP 1:1000, Dako; S100β
1:1000, Abcam; GS 1:1000, Millipore) diluted in blocking buffer at 4◦C overnight.
The blots were washed in TBST, incubated with secondary antibody for 1 h at RT,
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washed in TBST, incubated with super signal femto chemiluminescent substrate and
visualized on x-ray films.
4.2.5 RT-qPCR
RT-qPCR was performed using Sybr green master mix in the LightCycler 480 sys-
tem (Roche). Change in RNA levels was measured using the 2−δδCt method, where
CT is the crossing threshold value. Delta CT values were calculated by subtracting
the geometric mean of three housekeeping genes (β- 2 Microglobulin (β2m), succi-
nate dehydrogenase complex subunit A (Sdha), and signal recognition particle 14 kDa
(Srp14)) from the average CT value of the target gene. A no template control was
also used during each run. The primers used for analysis include gliosis markers in-
cluded in Table 2.2 as well as downstream targets of YAP/TEAD signaling (Table
4.1).
Table 4.1.
List of RT-qPCR primers
Gene Primer Sequence Length (bp)
Edn1 Forward GGCCCAAAGTACCATGCAGA 127
Reverse TGCTATTGCTGATGGCCTCC
Kif14 Forward GGGAGCAAGCTCTGTGTTCT 110
Reverse GGTCTCCAGCCCAGAGTCTA
Ets1 Forward GCCCGACTCTCACCATCATCA 102
Reverse AGCTTTCAAGGCTTGGGACA
Ets2 Forward ATGCTGTGTAACCTCGGCAA 95
Reverse CCGCGTTGAGGTGAGAGTTT
Myc Forward CGCGATCAGCTCTCCTGAAA 84
Reverse GCTGTACGGAGTCGTAGTCG
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4.3 Results
4.3.1 AMOTs and YAP are expressed in the glial cells in the retina
As a first step in determining if AMOTs and YAP may be critical to the gliosis re-
sponse, sections through adult murine retinas were co-labeled with antibodies that
label Mu¨ller glia and retinal astrocyte cells (SOX9 or glutamine synthetase; GS) and
YAP or AMOT (Figure 4.1). Both YAP and AMOT co-labeled with glial cell mark-
ers in the adult retina. While YAP showed nuclear co-localization, AMOT label was
cytoplasmic. YAP co-labeled with the nuclear Mu¨ller glia marker SOX2 (Figure 4.1
A–C). AMOT showed cytoplasmic distribution and co-labeled with the glial cytoplas-
mic marker, GS (Figure 4.1D–F).
YAP label was restricted to the inner nuclear layer where Mu¨ller cell nuclei reside,
while AMOT co-expressed with retina Mu¨ller cell processes that span the width of
the retina and potentially the retinal astrocytes in the nerve fiber layer.
4.3.2 AMOT and YAP upregulated during IFN-γ induces gliosis
Preliminary data from the Wells lab had shown that a luciferase construct under the
regulation of the AMOT promoter, showed increased activity following exposure to
IFN-γ and IL6 in HEK293 cells (unpublished data). Thus, the first step was to deter-
mine the changes induced in the retina following exposure to IFN-γ. Samples of eyes
injected with IFN-γ were assessed for changes in gliosis markers via immunofluores-
cence or RT-qPCR (Figure 4.2). Immunofluorescence label for gliosis markers GFAP
and S100-β was greater in the IFN-γ injected retinas as compared to the 4 d PBS
(vehicle for IFN-γ) injected retina (Figure 4.2A–F). Label for the gliosis markers was
greater 4 d following IFN-γ injection when compared to 1 d post IFN-γ injection
(Figure 4.2B, C, E, F). RT-qPCR was performed for a subset of gliosis markers using
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Fig. 4.1. AMOT and YAP expression in the murine retina. Reti-
nal sections labeled with antibodies against YAP and SOX9 (A–C)
and AMOT and GS (D–F). Merged images indicate co-localization
of YAP with the nuclear marker for glial cells, while AMOT colocal-
ization with GS suggests cytoplasmic localization in the retinal glia.
Magnification bar in A=50 µm, for all panels.
RNA from 4 d IFN-γ or PBS injected retinas. A relative increase in RNA levels of
gliosis markers Gfap, S100-β, Tlr4, Egfr and Ncan was observed in the IFN-γ in-
jected retinas.
Protein levels of AMOT and YAP were also assessed in retinas injected with IFN-γ or
vehicle. Immunofluorescence label revealed an upregulation of AMOT in the ganglion
cell layer and nerve fiber layer in the IFN-γ injected retinas (Figure 4.3 A–C), no vis-
ible change was observed in the localization of the YAP in the retinal glia (Figure 4.3
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Fig. 4.2. IFN-γ upregulates gliosis markers in the retina. Retinal sec-
tions from P30 mice injected with vehicle or IFN-γ were labeled for
gliosis markers (A–F) or analyzed for a subset of gliosis markers via
RT-qPCR (G). Immunofluorescence label of injected retinas showed
an increase in label for GFAP and S100-β in the IFN-γ injected reti-
nas, compared to the vehicle injected retinas.RT-qPCR anaysis of
RNA from IFN-γ injected retinas revealed an increase in levels of
Gfap, S100-β, Tlr4, Egfr and Ncan relative to RNA from the vehicle
injected retinas. Magnification bar in A=50 µm, for panels A–F.
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D–F). Western blot analysis was performed to determine changes in AMOT and YAP
protein levels during gliosis using the IFN-γ injected retinas. Protein levels of p80
and p130 isoforms of the AMOT was upregulated in the IFN-γ injected retina when
compared to the vehicle injected retina (Figure 4.3 G). Furthermore, AMOTL1 also
showed an increase in the IFN-γ injected retina (Figure 4.3 G). YAP levels were also
upregulated in the IFN-γ injected retina (Figure 4.3 H).
4.3.3 Verteporfin treatment decreases RNA levels of YAP/TEAD down-
stream targets
Verteporfin (VP), a small molecule inhibitor that prevents YAP from binding to
TEAD and thereby regulate target gene expression, was used to inhibit YAP sig-
naling in the glial cells. Mouse eyes were injected intravitreally with 20, 50 or 100
ng/µl VP and assessed for changes in the YAP downstream targets via RT-qPCR to
determine the efficacy of the inhibitor (Figure 4.4). 4d post treatment, a decrease
in four out of the five YAP downstream targets was observed in the mouse retina
treated with 50ng/µl when compared to the DMSO (vehicle) treated cells. In mice
treated with 20ng/µl significant decrease in the RNA levels of Edn1, Ets1 and Ets2
was observed, while in eyes injected with 100ng/µl VP, we observed significant de-
creases in Edn1 and Ets1.
4.3.4 Effect of IFN-γ on retinal gliosis in presence of verteporfin
To determine if YAP inhibition can regulate gliosis, adult mice were injected with
1µ lof 150ng/µl IFN-γ followed by an injection with 1µl of 20ng/µl or 50ng/µl verteporfin.
Samples were isolated from the injected eyes 4 d post injection and analyzed via RT-
qPCR (Figure 4.5) for changes associated with gliosis. RT-qPCR analysis revealed an
increase in RNA levels of Gfap, Vim, Gs, S100-β, Ncan and Mmp9 in the presence or
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Fig. 4.3. IFN-γ upregulates AMOT and YAP in the retina. Retinal
sections from P30 mice injected with vehicle or IFN-γ were AMOT
(A - C) and YAP (D - F). AMOT levels were upregulated in the
ganglion cell layer and nerve fiber layers in the 1 and 4 d IFN-γ
injected retinas compared to the vehicle injected retinas. Changes in
the protein levels were also quantified via western blot. β-TUBULIN
was used as aloading control for the western blots. Densitometric
analysis of blots revelaed an increase in AMOT levels in the IFN-γ
injected retinas relative to the vehicle injected retina. Upregulation
of AMOTp80, AMOTp130 and AMOTL1 were similar in the 1d and
4d IFN-γ injected retinas. YAP levels were upregulated by about 2
fold in the 4d IFN-γ injected retinas, while only a 1.5 fold increase
was observed in the 1d IFN-γ injected retinas. Magnification bar in
A=50 µm, for panels A–F.
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Fig. 4.4. Verteporfin downregulates RNA levels of downstream YAP
targets. Adult mice injected intravitreally with different concentra-
tions of verteporfin compared with the vehicle controls analyzed for
downstream YAP target via RT-qPCR. Graphs represent a log2 fold
change in the RNA levels of eyes injected with verteporfin relative to
the vehicle injected control eyes. Statistical analysis was performed
by unpaired Students t test. ∗, # and θ represent a p value <0.05
between the 20ng/µl, 50ng/µl and 100ng/µl inhibitor injected eyes
and their respective vehicle controls. A significant decrease in Edn1
and Ets1 was observed in the three concentrations tested. Addition-
ally, Ets2 was decreased in eyes injected with 20ng/µl and 50ng/µl of
verteporfin and Myc was decreased in the eyes injected with 50ng/µl
of the inhibitor.
119
absence of verteporfin in the IFN-γ injected retinas (Figure 4.5). However, Vim RNA
level was upregulated following VP treatment. Furthermore, RNA levels of Tlr4, Egfr
and extracellular matrix markers Ncan and Pcan were decreased following 20ng/µl
VP treatment, while Gs, S100-β, Egfr, Pcan and Mmp9 were decreased in the eyes
co-injected with IFN-γ and 50ng/µl of VP.
4.4 Discussion
This study revealed that AMOT and YAP are expressed in the macroglial cells in the
retina. While AMOT expression was observed in the Mu¨ller glial fibers and retinal
astrocytes, YAP was expressed in the nuclei of Mu¨ller glia. The increase in AMOT
and YAP levels correlated with increase in gliosis markers in the retina. Furthermore,
inhibiting YAP/TEAD binding decreased RNA levels of ECM markers in IFN-γ in-
jected retinas, but did not return Vimentin and GFAP to normal levels.
In the murine retina, we observed that AMOT and YAP were expressed in the glial
cells. In the eye, the Hippo pathway has been known to regulate eye development by
regulating proliferation and inhibiting apoptosis of the retinal progenitors to gener-
ate sufficient cells prior to differentiation [235]. YAP knockout has associated with
reduced eye size [236]. Furthermore, the Hippo pathway also regulates patterning of
the retina. Activation of the Hippo pathway prevents nuclear localization of YAP,
allowing the transcription factor Rx1 to activate photoreceptor genes Otx2, Otx5 and
Crx [237]. Downregulation of the Hippo pathway leads to the nuclear localization of
the YAP analog in drosophila, Yki, leading to proliferation of retinal progenitors and
activation of Wg which prevents pre mature differentiation of the retinal cells [238].
The significance of YAP has also been established in differentiation of glial cells.
Huang et al. 2016 demonstrated that nuclear YAP stabilizes pSMAD in neural stem
cells, promoting astrocyte differentiation [223, 239]. YAP overexpression maintained
the stem cells in a proliferative state, while neuronal differentiation was rescued by
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Fig. 4.5. Inhibition of YAP in IFN-γ injected retina. RT-qPCR of
RNA from samples co-injected with verteporfin and IFN-γ or vehicle
were analyzed for gliosis markers. Graphs represented are fold change
in treatments relative the vehicle and verteporfin co-injected samples.
RNA from IFN-γ injected retinas showed a two fold increase in levels
of Gfap,Vim, Gs, S100-β and Ncan. In the presence of the inhibitor,
RNA levels of Vim was upregulated in the 20 and 50 ng/µl verteporfin
injected retinas. S100-β and Mmp9 were also elevated over two fold in
the retinas injected with IFN-γ and 20ng/µl verteporfin, while Gfap
and Ncan was upregulated in the in the retinas injected with IFN-γ
and 50ng/µl verteporfin.
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knockdown of Gli2. While YAP can regulate the proliferation of progenitor and stem
cells in various tissues and organs including the retina and brain, its role in regulating
the regenerative potential of Mu¨ller glia is yet unexplored. The regenerative activity
of Mu¨ller glia is limited in mammals although treatment with factors such as CNTF
and FGF have been shown to induce proliferation in the Mu¨ller glia in the mouse
retina. However, in lower vertebrates such as zebrafish Mu¨ller glia have been shown
to undergo proliferation and de-differentiate into retinal neurons [240, 241]. Thus,
regulation of YAP/Hippo pathway could be the underlying mechanism mediating the
regenerative potential of Mu¨ller glia.
Regulation of Hippo pathway has been observed following injury in the skin and
intestinal tissues. YAP regulates TGF-β signaling in skin fibroblasts following in-
jury and mediate wound healing. Knockdown of YAP and its co-factor TAZ lead to
an increase in the wound closure time indicating its importance in injury response
in the skin [242]. Similarly, YAP overexpression has been shown to inhibit growth
and regeneration of the intestine in mouse by regulating Wnt signaling [243]. The
regenerative and proliferative properties of the Hippo/YAP signaling could be indica-
tive of a role for this pathway in regulating the gliosis response following injury or
disease. Glial cell activation has been associated with activation of signaling path-
ways such as TGF-β, Wnt, Notch, CNTF and inflammatory markers such as IFN-γ
and TNF-α. YAP mediated stabilization of SMAD, a downstream component of the
TGF-β signaling has been reported in the retina, intestine, liver and skin fibroblasts.
Hippo mediated regulation of Notch and Wnt signaling has also been described in
the intestine and liver, respectively. Furthermore, recent reports have described YAP
regulation during gliosis [239,244].
While we observed an increase in AMOT and YAP expression following treatment
with IFN-γ, Huang Z et al., 2016 observed an increase in YAP in mouse brain as-
trocytes following treatment with CNTF and IFN-β. Furthermore, YAP was found
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to interact with phospho-STAT3 and induced expression of SOCS3 to inhibit inflam-
matory response, with YAP knockout astrocytes displaying a hyper inflammatory
response. Hamon A et al., 2017 re-affirmed the expression we observed in our stud-
ies. Using a mouse model for retinal degeneration (rd10), they showed that YAP
and its co-transcription factor TEAD are expressed in the Mu¨ller glia and that they
are upregulated in the diseased retina [244]. Furthmore, downstream targets of the
Hippo/YAP pathway such as Cyr61 and Ctgf have also been observed to be upregu-
lated in models of retinitis pigmentosa, diabetic retinopathy and glaucoma.
Another related response we observe is an increase in the expression of AMOTs in the
retina during gliosis. Two different isoforms of AMOTs (AMOTp130 and AMOTp80
lacking an N terminal domain) are known to be expressed along with AMOT like1
(AMOTL1) and AMOT like 2 (AMOTL2). While AMOTp130, AMOTL1 and AMOTL2
have been shown to interact with YAP and localize it to the cytoplasm, AMOTp80
which lacks the N-terminal domain serves as a dominant negative form inhibiting the
AMOT interaction with YAP [231]. In the retina, AMOTp80 is known to mediate
endothelial cell migration during angiogenesis, while AMOTp130 mediated stabiliza-
tion and maturation of the retinal vasculature [245,246]. Here we observe an increase
in the levels of both isoforms of AMOT. We propose that AMOTs expressed in the
glial are also involved in stabilizing the Mu¨ller glia and maintaining cell-cell contacts.
During gliosis, AMOTp80 oligomerizes with AMOTp130 disrupting Mu¨ller glia sta-
bilization and making the cell conducive for the changes of gliosis. Furthermore, this
interaction removes the inhibition on YAP, which is translocated to the nucleus and
can further regulate the gliosis response. However, it will be important to further
explore the interactions of AMOTs in the retinal glia.
Our experiments where mice were injected with a YAP/TEAD inhibitor revealed a
decrease in RNA levels of some of the gliosis markers following IFN-γ treatment.
However, Gfap, Vim and S100β levels were similar to the IFN-γ injected retinas
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not treated with verteporfin. It has been previously mentioned that YAP binds to
its target genes through association with co-factors, primarily TEAD. However, re-
search has revealed that YAP can also bind with other co-factors such as SMAD and
β-catenin to mediate gene regulation. While its interaction with TEAD has been
inhibited, its interaction with other co-factors could also be involved in regulation
of gliosis. Thus, it will be essential to examine AMOT YAP interactions, protein
modification to YAP as well as the co-transcription factors which can interact with
nuclear YAP in the retinal glia.
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5. DISCUSSION
The changes caused due to gliosis has been described as having both beneficial and
detrimental effects on the surrounding tissue. While it was initially described as in-
hibitory to the neural tissue due to scarring, proliferation and inflammatory responses,
knockout studies revealed that gliosis is essential to limit the spread of lesion following
injury to neurons [43]. Changes during the early phases of gliosis such as hypertro-
phy, upregulation of glutamate uptake, increased reactive oxygen species scavengers
and water and ion uptake have been shown to be essential in limiting the spread
of injury in the tissue [43]. Gliosis also leads to increase in release of factors such
as BDNF and FGF which are essential for neuronal survival. However, prolonged
gliosis can lead formation of glial scars which prevent axon regeneration, an increase
in the inflammatory response, disruption of normal functions which otherwise help in
maintaining tissue homogeneity as well as alter the barrier functions of the associated
blood vessels causing further damage to the tissue [42].
The activated microglia mediated inflammatory changes is essential in responding to
early injury/disease states, however, like gliosis, long term activation of the microglia
can have detrimental effects on the tissue [14]. The activated microglia have been pro-
posed to exhibit two functionally distinct phenotypes: the M1 or pro-inflammatory
phenotype and the M2 or anti-inflammatory phenotype. While the two classes of acti-
vated microglia are distinguished on the factors secreted/markers expressed, research
suggests that microglia transition from an initial M1 phenotype to the M2 phenotype
before returning to its resting state. The early response of the microglia is essential
as it signals migration of the microglia to the injury site, increase phagocytosis and
debris clearance, and recruiting more microglia to aid in damage limitation. The
transition of microglia from this state to a M2 phenotype leads to increase in signals
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which aid in neuronal survival, ECM remodeling and decrease of the pro-inflammatory
signals [55]. Similar to the gliosis response of the macroglia, prolonged activation of
the microglia leads to an increase in pro-inflammatory signals which can in turn lead
to further tissue damage as well as activation of the macroglia.
In the retina, gliosis is observed in all diseases and injuries. Triggers identified so far
include reactive oxygen species such as NO, physical stress or injury, increased neuro-
transmitter release from neurons, leaky blood vessels as well as inflammatory factors.
In vitro studies as well as various model organisms have revealed that factors such
as CNTF, LIF, EGF and TNF-α are regulated during gliosis. While several factors
have been identified, the underlying mechanism regulating gliosis is still not clearly
understood. How the various triggers identified in different disease and injury models
bring about certain similar gliosis responses is essential to understanding approaches
to tissue repair. Furthermore, being able to delineate between the detrimental and
beneficial changes of the glial cells will aid in tissue regeneration.
In this study we have identified BMP7 as one of the triggers of gliosis in the retina.
To determine this effect we developed a panel of markers encompassing a wide range
of changes previously reported by other researchers. RT-qPCR data from our initial
studies indicate that while BMP7can trigger gliosis in the retina glia, prolonged ex-
posure to BMP7 may be involved in regulating the extracellular matrix remodeling.
While we do observe an increase in RNA and protein levels of the inhibitory CSPG
neurocan, we also do observe an increase in RNA levels of MMPs as well as tissue
inhibitors of MMPs. Regulation of CSPGs via SMAD signaling in astrocytes has
been described by [77, 247]. The CSPGs have also been shown to be regulated by
non-canonical TGF-β signaling in rat cortical astrocytes via the PI3K-AKT-mTOR
signaling pathway [72]. In our experiments with BMP7 treatments, we observed an
increase in phospho SMAD levels as well as increase in the expression of phospho
TAK in the retinal glia. Similarly, MMPs are also regulated by SMADs and other
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transcription factors such as STATs and NF-κB [248]. Thus, further studies looking
into regulation of the BMP signaling mechanism, its effect on other growth factors
and inflammatory factors will help provide a better understanding of extracellular
matrix remodeling.
While the glial cells are essential in formation of the blood retinal barrier, activa-
tion of the retinal glia leads to barrier breakdown due to loss of gap junctions and
signaling between the glia and the cells of the vasculature [42,102]. Alternatively hy-
perglycemia, hypoxia, oxidative stress and inflammatory signals also affect the cells
of the vasculature leading to dysfunction of the blood vessels and increased leakage,
in turn leading to gliosis [45]. BRB disruption has been described in several retinal
injury/disease models and can also lead to extravasation of macrophages into the
retina, which can exacerbate the inflammatory response and compound the gliosis
response. The resident macrophages of the retina are the microglial cells, which also
undergo activation in retinal disease and injury state. Activation of the microglia
has been described in various models of retinal diseases including glaucoma, diabetic
retinopathy, AMD and RP, where these cells induce secretion of inflammatory cy-
tokines and chemokines [125]. The factors secreted by the activated microglia such as
TNF-α, IFN-γ and IL have been shown to regulate gliosis in the Mu¨ller glia and reti-
nal astrocytes (Karlstetter et al. 2015). Mu¨ller glial cells regulate the resting state of
microglia through ATP secretion [165]. In a model of retinal degeneration, microglia-
Mu¨ller glia interaction mediates the release of neurotrophic factors bFGF and GDNF
to enhance neuronal survival [194]. Wang et al., 2011 further demonstrated that acti-
vated microglia induce Mu¨ller glia to express inflammatory cytokines and chemokines
to maintain the microglia in an activated state as well as mediate microglia migration
to the injury site [59]. We have demonstrated in our studies that microglia, along
with the Mu¨ller glia, respond to BMP7 stimulation and undergo activation upregu-
lating expression of various inflammatory cytokines. Decrease in expression of gliosis
markers following ablation of microglia strengthens the importance of microglia in
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regulating the gliosis response. Inflammatory cytokines upregulated by microglia fol-
lowing disruption of retinal homeostasis could be essential in regulating the gliosis
response.
We propose that BMP7 is able to regulate gliosis via the following pathways: BMP7
triggers upregulation of factors and markers associated with gliosis in the macroglia.
It leads to an increase in BMP7 secretion from the Mu¨ller glia in an autocrine man-
ner to trigger further gliosis. BMP7 could also upregulated secreted factors such as
LIF, which has been shown by other researchers to trigger gliosis. Simultaneously, the
BMP7 activates the retinal microglia. The activated microglia upregulate factors such
as GM-CSF, IFN-γ and IL-6. These factors recruit more microglia and activate them.
Furthermore, factors such as IFN-γ and IL-6 could also trigger gliosis and prolong the
gliosis response in the retina (Figure 5.1). Inhibition of signaling between the glial
populations could serve to develop therapeutic approaches to treat retinal injuries/
diseases. By intervening at the appropriate time by ablating the microglia and/or
inhibiting signals from microglia, prolonged gliosis and/inflammatory response can be
curtailed which can potentially help in neuronal survival and an improved recovery
of retinal function.
We have described previously the different growth factors regulated in the various reti-
nal injury and disease models. Whether there is a common underlying pathway which
regulates a somewhat similar gliosis response in the different injury conditions is not
known. The Hippo pathway could be a central pathway linking the gliosis response
in various conditions as crosstalk with other pathways such as TGF-β, CNTF, and
TNF-α and the Hippo pathway has been established. In the various retinal diseases
such as glaucoma, AMD, retinal degeneration and diabetic retinopathy, different fac-
tors or group of factors have been determined to play a role in regulation gliosis and
progression of the diseased phenotype (see introduction). However, in all diseases,
upregulation of GFAP has been observed starting at a particular stage of disease
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Fig. 5.1. Proposed model of BMP7 mediated regulation of retinal glio-
sis. BMP7 triggers a response in the Mu¨ller glia as well as microglia
leading to secretion of factors such as IFN-γ, IL-6 and GMCSF. These
factors could potentially mediate the gliosis response following BMP7
treatments.
progression. Other common changes include increase in expression of inflammatory
markers, upregulation of neuroprotective factors and factors which regulate the blood
retina barrier properties. Transcription factors such as SMAD, STAT and NF-κB are
known to regulate the genes associated with gliosis such as GFAP, vimentin, Kir4.1
and interleukins. This suggests one of two possibilities for the common regulatory
events of gliosis influenced by different factors: 1) regulation of non-canonical signal-
ing via growth factors leading to activation of multiple transcription factors which
leads to similar change;.for example, BMP signaling which can signal via SMADs or
non-canonically via TAK leading to activation of p38/MAPK signaling to regulate
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target genes, and 2) a common pathway activated by the different stresses that can
trigger gliosis. The Hippo pathway can be regulated by growth factors, physical stress
as well as factors such as ATP [249]. While regulation of Hippo pathway has been
shown to be important in regulating retinal progenitor cell fate, its expression in the
mature retina is not known. The results from this study as well as recently published
data from Muriel Perrons lab show that AMOTs, YAP and TEADs are co-localized to
the retinal glia [244]. Furthermore, regulation of Hippo-YAP signaling was observed
in this study in retinas where gliosis was induced by IFN-γ injection, as well as in
Hamon et al., 2017 mouse model of retinal degeneration. While we observed that
inhibition of YAP/TEAD association decreased RNA levels of extracellular matrix
molecules following IFN-γ treatment in the retina, Huang et al., 2016 observed that
YAP knockout in development lef to hyperactivation of inflammatory response in pri-
mary brain astrocyte cultures [250].
We observe in the mouse retina that most of the YAP is localized in the nucleus
of the Mu¨ller glia in wild type and the IFN- induced gliosis retinas. Furthermore,
mammalian Mu¨ller glia exhibit proliferation in vitro or in show limited proliferation
in the mouse retina [244]. This could be suggestive of a different role for YAP in
the Mu¨ller glia. We propose that YAP in the murine retina serves as the common
factor linking the response of the Mu¨ller glia to various gliosis inducing factors such
as Wnts, TGF-β and IFN-γ (Figure 5.2). However, further studies need to be carried
out to determine what aspects of gliosis are regulated by Hippo/YAP signaling and
the specific interactions between the Hippo components and gliosis triggers in the
retina.
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Fig. 5.2. Potential role of YAP as the common factor in regulating
gliosis. YAP potentially regulates some of the responses associated
with gliosis in retina. Furthermore, evidence of YAP interaction with
transcription factors such as STAT and SMAD could suggest a poten-
tial role for YAP playing a central role in regulating certain common
glial changes in response to different factors.
5.1 Future directions
The aim of this thesis is to characterize the gliosis response in the retina and the
role of BMP7 in regulating this response. Using in vitro and in vivo approaches, we
were able to show the mechanism for regulation of gliosis in the retina, which can
be used for future research to help in manipulating gliosis to aid in functional recovery.
Throughout the studies we have primarily looked at RNA levels of gliosis markers
representing various physiological changes in the glia. A subset of these markers were
analyzed at the protein level. While this data does provide sufficient insight into the
regulation of glial characteristics, future studies describing protein levels of the mark-
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ers would be essential to elucidate the response in the glial cells. In chapter 2 and 3
of the studies, we observed differences in the levels of protein and RNA in the retinas
induced treated with exogenic factors. This could be indicative of deregulation of the
translation machinery, RNA stabilization or post translation modifications. Thus, it
would be imperative to look into the regulation of proteins to provide a complete
picture of regulation of gliosis in the retina.
In chapter 2, we showed that BMP7 triggers gliosis in the retina via activation of
the canonical SMAD and non-canonical TAK pathway. This conclusion was based on
the observation of the phosphorylated forms of these downstream signaling molecules.
Thus, determining if gliosis is triggered preferentially by one pathway or the other,
as well as identifying the downstream targets of these pathways in the retinal glia
would be beneficial in developing treatments/inhibitory cues to prevent a prolonged
gliosis response. While we observed an increase in phospho SMAD and phospho TAK
levels in the retina, the source for BMP is still unclear. Identifying the source of BMP
could be essential in developing treatment to aid in functional recovery in the retina
by inhibiting long term changes of gliosis by blocking BMP signaling.
In chapter 3, we defined a model for reactive gliosis in the retina requiring activation
of microglia. In our study we ablated retinal microglia for a maximum of 21 days and
observed a decrease in BMP7 induced gliosis following microglial ablation. Further,
we observed an increase in RNA levels of IL6 and RNA and protein levels of IFN-γ
in the microglia following BMP7 treatment. Further work needs to be done 1) to
determine if IL6 protein levels also increase corresponding to the RNA levels and 2)
to determine if treatments with IFN-γ, IL6 and other growth factors (such as BMP)
is sufficient to trigger gliosis in the absence of microglia. It would also be important
to identify long term effects of microglia ablation on retinal function.
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A more detailed study of the Hippo pathway in retinal gliosis will be essential in
1) determining if this pathway could be central to regulation of gliosis in different
diseases and 2) if deregulation of the Hippo/YAP pathway can induce glial cells in to
de-differentiation to generate retinal neurons lost due to injury or disease. In chapter
4, we described the expression of AMOT and YAP in the retina under normal condi-
tions and in IFN-γ induced gliosis. The inhibitor used in the study, which blocks the
interaction of YAP with TEADs to prevent activation of YAP/TEAD targets, lead to
a decrease in the RNA levels of extracellular markers. Thus, it would be important to
determine if this change is translated to the protein level. Future studies should also
be aimed at determining if inhibition of YAP in disease models can aid in functional
recovery or if YAP overexpression can induce proliferation and de-differentiation of
Mu¨ller glia to aid with regeneration. Furthermore, overexpression or loss of expres-
sion of AMOT in the retinal glia should also be performed in disease models or gliosis
induced retinas to determine the mechanism of regulation of Hippo/YAP pathway
during gliosis.
Overall, these studies outlined above will provide more insight into the mechanism
regulating retinal gliosis. This will help in studies which can lay the foundation to
identify appropriate timepoint in the gliosis response which mediates the switch from
beneficial to detrimental effects. The topics explored in this thesis have provide a
basis for understanding gliosis regulation which can ultimately lead to development
therapeutic approaches which can aid in the functional recovery as well regeneration
in the retina.
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